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ABSTRACT
PALMITOYLATION AND POLARITY: ASYMMETRIC PARTITIONING OF NOTCH AND
WNT SIGNALING BY REVERSIBLE LIPID MODIFICATION IN DIVIDING CELLS
Ewa Stypulkowski
Eric S. Witze
Protein palmitoylation is a reversible lipid modification that regulates protein-membrane
interaction, activity, trafficking, and stability in a spatio-temporal manner similar to
phosphorylation and ubiquitination. Asymmetric cell division results in two distinctly fated
daughter cells, by unequally partitioning proteins known as cell fate determinants. I have
characterized a mechanism for protein palmitoylation to asymmetrically partition cell fate
determinants, e.g. Numb and β-catenin, through the activity of the depalmitoylating enzyme
APT1. Using point mutations, I have found specific palmitoylated residues on Numb are required
for its asymmetric localization in dividing cells. By live-cell imaging, I have also identified a
reciprocal interaction between APT1 and the Rho family GTPase, CDC42, which promotes
asymmetric localization of Numb and β-catenin to the plasma membrane. In turn, this
mechanism restricts Notch- or Wnt-responsive transcriptional activity to one daughter cell.
Moreover, I show that altering APT1 expression levels alters the transcriptional signatures of
MDA-MB-231 triple receptor-negative breast cancer cells, resembling altered Notch and βcatenin-mediated Wnt signaling. Furthermore, loss of APT1 depletes a specific subpopulation of
tumorigenic cells. Together, this dissertation presents palmitoylation as a major mechanism of
asymmetric cell division that maintains Notch- and Wnt-associated protein dynamics, gene
expression, and cellular functions.
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CHAPTER 1: INTRODUCTION

1.1 Summary
Significant effort has gone into elucidating the molecular mechanisms regulating the
polarized protein localization of proteins in cells and tissues during development, homeostasis,
and disease. Lipid modification is a class of post-translational modifications that facilitates and
stabilizes protein targeting to intracellular membrane domains. This enables the formation of
polarized signaling domains at the membrane to propagate downstream signal transduction.
Protein palmitoylation is a reversible lipid modification that regulates protein-protein and proteinmembrane interaction, activity, trafficking, and stability in a spatio-temporal manner similar to
phosphorylation and ubiquitination. Despite an evolutionarily conserved requirement for
palmitoylation on many key cellular processes, numerous technical challenges have made it
difficult to study palmitoylation in real-time and in situ. These obstacles include a lack of
antibodies to palmitoylated domains and live-cell imaging probes to measure palmitoylation at
the single cell level. In this chapter, I will discuss the evidence, technological advances, and
emerging roles for palmitoylation on protein function and cellular processes.

1.2 Overview
Cellular responses to intrinsic (genetic) cues or extrinsic (environmental) signaling cues
are essential to drive polarized behaviors essential for embryonic development and tissue
homeostasis such as axial patterning, convergent extension, wound healing, and tissue
morphogenesis (1, 2). Within the cell, molecular mechanisms drive the polarized segregation of
1

signaling effectors to specialized plasma and endomembrane domains in response to extrinsic and
intrinsic cues to facilitate protein-protein interactions (3, 4). Formation of these polarized
domains, e.g. apical/basolateral, allows various parts of the cell to carry out specialized functions
such as cell migration, invasion, and asymmetric cell division (1). Processes such as germ layer
specification, differentiation, and proliferation require precise spatio-temporal regulation of
various signaling pathways at distinct subcellular domains. In addition to spatial localization, the
protein-protein interactions must be temporally regulated for proper development and tissue
function. Loss of polarized protein localization may promote the excessive or insufficient
duration signaling activity, resulting in developmental disorders (including embryonic lethality),
neurodegenerative disorders, and cancer (3, 5, 6).
Soluble, cytosolic proteins can localize to the membrane through random diffusion;
however, these transient interactions are insufficient to propagate a signal over time (4, 7–9).
Polarized protein localization is widely regulated by post-translational modifications that alter the
structure and biophysical properties of proteins to modulate activity, stability, protein-protein
interaction, and subcellular localization, and include phosphorylation, acetylation, ubiquitination,
methylation, and lipid modification (4, 10–12). Post-translational lipid modification increases the
hydrophobicity of cytosolic proteins, which enables recruitment and stable association with lipid
rafts and other membrane domains. This stable association can bring signaling effectors into close
proximity of each other to propagate signaling cascades that, in turn, influence cell identity and
function (6, 13–16).
Myristoylation, prenylation, and palmitoylation are three of the most common lipid
modifications; palmitoylation is unique in that the modification can be enzymatically reversed.
Because of its dynamic properties, palmitoylation spatio-temporally modulates protein activity,
stability, and transport between intracellular compartments, a key requirement of establishing cell
2

polarity (4, 6, 12). In this manner, palmitoylation is regarded as a regulatory switch similar to
phosphorylation or ubiquitination (6, 16–18).
First studied in viruses in the late 1970s, palmitoylation has since been examined in
bacteria and eukaryotes from yeast to humans (11, 18–23). It plays a role in diverse cellular and
developmental processes including, but not limited to, receptor kinase activity (24–33), ion
channel function (32, 34–41), apoptosis (29, 42–44), immunomodulation (45–50), cell junction
assembly (51–55), cellular senescence (56–58), genomic stability (24, 59–62), neural cells
development (63, 64), and progenitor cell maintenance (25, 55, 65–67). Palmitoylation also
maintains the activity of signaling pathway such as Wnt (68–71), G-protein coupled receptor (9,
11, 72, 73), epithelial growth factor receptor (26, 27, 74), and Ras (9, 11, 75, 76). Disruption of
palmitoylation has been linked to the pathogenesis of diseases from Huntington’s disease (77–
80), Alzheimer’s disease (44, 81–83), neuropsychiatric disorders (84–87), cancer (26, 60, 70, 71,
88–94), and exploratory studies may implicate aberrant palmitoylation on metabolic disorders
(35, 95–97), and musculoskeletal defects (39, 40, 98–101). These examples highlight the diverse
biological functions regulated by palmitoylation, although may substrates and the regulation of
palmitoylation during these processes still remain to be determined.
Uncovering how palmitoylation regulates protein interactions and localization within a
cell may open new opportunities for understanding how signaling pathways are coordinated
within an organism to ensure proper development and homeostasis, and how these pathways are
dysregulated in disease which may advance the development of targeted therapeutic strategies.
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1.3 Introduction to protein palmitoylation
Palmitoylation is the covalent linkage of a 16-carbon palmitate group to a cysteine
residue via a labile thioester bond (16, 18, 22). Unlike myristoylated or prenylated proteins,
where the lipid group generally remains attached for the protein’s lifetime, palmitate is
dynamically turned over. The rate of palmitate turnover varies between substrate as some
proteins (TEAD, SNAP25 and synaptotagmin I) remain palmitoylated for hours, while others
(Ras, CDC42, Lck, and PSD-95) are rapidly depalmitoylated within minutes (11, 15, 102). This
turnover allows regulation of protein trafficking and sorting between membrane compartments
like the Golgi, endoplasmic reticulum, and plasma membrane (4, 12, 14) (Fig. 1.1 A).
Palmitoylation can also modulate the conformation and activity of transmembrane receptors and
other integral membrane proteins to facilitate downstream activity by regulating the association
between the cytosolic tail and the membrane to restrict or promote access to binding partners (4,
6, 12, 17) (Fig. 1.1 B). Hydrophobic protein pockets can be palmitoylated to restrict accessibility
to catalytic clefts, and palmitoylation can sterically hinder amino acid residues from
ubiquitinating enzymes to inhibit protein degradation (6, 10) (Fig. 1.1 C). These examples
demonstrate how palmitoylation can modulate cellular responses (12–14).
A single lipid group is generally not sufficient to maintain a stable protein-membrane
interaction, and therefore, proteins are dual-lipid modified with palmitate and another lipid group
(4, 9). Proteins containing a single prenyl or myristate group, such as Ras, Fyn kinase, or Gα
subunits, briefly associate with membranes (4, 9). Adding a second lipid group increases the
amount of time a protein resides at a membrane, thus promoting a sustained downstream signal
cascade (4, 9, 10, 14). For example, prenylated Ras preferentially localizes to the Golgi, but the
addition of palmitate drives its localization to plasma membrane. Regulated cycling between the
Golgi and plasma membrane maintains appropriate Ras distribution within the cell to keep Ras
4

signaling in check (4, 9). Inhibiting depalmitoylation with small molecule agents results in
nonspecific intracellular localization and downregulated Ras signaling (9, 75, 103). A member of
the Src family of kinases, Lyn, is dually myristoylated and palmitoylated; this is thought to
prevent chromosome missegregation by restricting Lyn at the plasma membrane and preventing
nuclear translocation (24). Dual lipid modification also facilitates the cycling of neuronal synaptic
proteins PSD-95 and GAP43 cycle between the cytosol and synaptic membranes or axonal
outgrowths (9, 11, 14). These examples demonstrate how palmitoylation serves as a critical
mechanism to spatio-temporally regulate protein localization to maintain signaling activity and
protein interactions, such as ligand-receptor interactions (17).
While the majority of palmitoylated proteins undergo enzymatically regulated cycles of
palmitoylation and depalmitoylation, a smaller number of palmitoylated proteins are irreversibly
modified (10). Ligands and hormones like Spitz (an EGFR-activating ligand), Hedgehog, Wnt,
and preghrelin are irreversibly palmitoylated, which facilitates proper post-translational
processing and secretion out of the cell (9, 10, 16). Although a recent study identified Wnt
ligands are depalmitoylated by Notum (104), irreversibly palmitoylated proteins are not known to
cycle between palmitoylated and unpalmitoylated states as reversibly modified proteins do. While
irreversible palmitoylation is critical for cell signaling, this chapter will discuss the biological
function of the more ubiquitously studied reversible palmitoylation.

1.4 Enzymatic regulation of palmitoylation-depalmitoylation cycles
Palmitoylation is catalyzed by two classes of evolutionarily conserved enzymes:
palmitoyltransferases and depalmitoylating enzymes (9, 10) (Fig. 1.2). The multi-pass DHHC
transmembrane proteins make up the largest class of palmitoyltransferases. This family was first
5

isolated in yeast and is characterized by a cysteine-rich domain containing a highly conserved
DHHC (Aspartate-Histidine-Histidine-Cysteine) zinc-finger motif (105–107). The number of
DHHC enzymes varies with species, e.g. 7 in yeast, 23 in mammals, 24 in plants and
invertebrates (D. melanogaster) (16, 18, 23). As a large group, DHHCs share many functional
redundancies and substrates. Unlike myristoylation or prenylation, which have defined substrate
recognition sequences, palmitate can be added to any cysteine (10, 22). Because of this, a defined
palmitoylation-recognition sequence has not yet been identified making it difficult to predict
palmitoylated proteins based on amino acid sequence. Ankyrin-repeat domains have been
suggested as a potential DHHC recognition sequence (15, 108, 109). Specific substrate-DHHC
pairs have also been observed depending on tissue context, cellular compartment, or even amino
acid sequence (15, 23, 110). Due to the abundance of palmitoylated proteins, the size of the
DHHC famil, and ambiguity in substrate-DHHC specificity have made it challenging to
characterize bona-fide substrate-enzyme pairs in vivo (14, 17).
Palmitate transfer from enzyme to substrate is a two-step process, which involves
forming a palmitate-DHHC intermediate through autopalmitoylation. Upon substrate binding,
palmitate is transferred from the DHHC to cysteine residues on the substrate though a thioester
bond (111). While free palmitate is abundantly found in the cell, palmitoyl-CoA is the source of
palmitate for DHHC enzymes (17, 112). DHHC enzymes are localized on various intracellular
membrane domains including the Golgi, endoplasmic reticulum, vesicles, and plasma membrane
(6, 15). Palmitoylation occurs both at the Golgi, where all palmitoylated proteins are trafficked
out to cellular domains, and at local membrane domains, raising the possibility that
palmitoylation may be spatially restricted to occur in proximity of palmitoyltransferases (113,
114). DHHC expression and localization may also be cell-cycle and tissue dependent (6, 15, 24,
62, 102, 115, 116). Segregating DHHCs to distinct compartments may serve as nucleating factors
6

to enrich for palmitoylated proteins at distinct membrane domains as in synaptic membranes,
focal adhesions, and in asymmetrically dividing cells. This may ensure palmitoylation occurs at
correct cellular compartments to regulate signaling activity (15, 46, 52, 71, 113).
Depalmitoylating enzymes make up a much smaller group and the mechanism of
depalmitoylation remains unclear; however, structural analysis suggests members may belong to
the larger α/β hydrolase family (6, 9). Acyl-protein thioesterases 1 and 2 (APT1 and APT2) and
protein palmitoyl-thioesterases 1 and 2 (PPT1 and PPT2) are among the best-studied
depalmitoylating enzymes (6, 9, 15, 23). APTs are primarily cytosolic proteins and transiently
localize to membranes to catalyze depalmitoylation (6, 117). While the lack of a defined
palmitoylation sequence has made identifying specific APT substrates challenging, most
reversibly-palmitoylated proteins including Ras, MCAM, and Gα subunits, appear to be targets
(15, 23, 70–72, 75). In contrast, PPTs are thought to be restricted to lysosomes to depalmitoylate
substrates targeted for degradation (14, 118). The ABHD17 family and orthologs, a subset of the
α/β hydrolase family, are newly identified depalmitoylating enzymes in mammalian cells and in
parasites. Whether the substrate pool for ABHD17 enzymes is as diverse as for APTs remains to
be determined (12, 18, 119).
Palmitoylation may also be regulated at the transcriptional level adding another layer of
spatio-temporal regulation of protein localization and signaling activity. Micro-RNAs and SNAIL
have been shown to regulate the expression of palmitoyltransferases and depalmitoylating
enzymes, and may contribute to dysregulated palmitoylation-mediated protein signaling in
disease (17, 73, 120, 121).
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1.5 Function of palmitoylation in protein trafficking, activity, and stability
Similar to phosphorylation or ubiquitination, palmitoylation modulates intracellular
trafficking, activity, and stability, and is regarded as a regulatory switch for proteins (17). The
role of palmitoylation on polarized protein trafficking has been best characterized in neural cells,
especially at the synapses (6, 11, 12, 14). Synapses are polarized structures that relay
electrochemical signals from dendrites to axons between adjacent neurons, and the polarized
trafficking of synaptic proteins is essential for transmitting these signals between neurons (11,
122). During neurotransmission, synaptic proteins including PSD-95, AMPA receptors, GABA
receptors, NMDA receptors, δ-catenin, GRIP1, SynDIG1, SNAP-25, and synaptotagmin-1,
shuttle between the cytosol, Golgi, vesicles, and synaptic membrane by palmitoylation (11, 14,
34, 55, 77, 78, 108, 123–127). The immune synapse is similarly polarized when lymphocytes
come in contact with target cells, which is required to activate lymphocyte function. Like in the
neural synapse, palmitoylation regulates the shuttling of CD4, CD8, LAT, Lck/Fyn kinases
between organelles and the synaptic membrane (48, 50, 128–130).
As mentioned earlier, Ras is palmitoylated at the Golgi to localize to the plasma
membrane where it interacts with binding partners. Similarly, depalmitoylation keeps Ras
signaling activity in check by localizing it back to the Golgi where it is inactive (9, 14). As a
small GTPase, Ras interacts with effectors PI3K, PLCξ, and RAF at the plasma membrane in its
active, GTP-bound form. In its inactive GDP-bound form, Ras is localized to the Golgi for
reactivation (131). Expression of palmitoylation-deficient mutant Ras or small molecule
inhibition of APTs disrupts Ras activation and intracellular localization (76, 103). Thus, the
spatiotemporal regulation and distribution of Ras signaling activity requires palmitoylation (103,
132). Fyn and GPCR activation cycles and intracellular shuttling between the Golgi to the plasma
membrane are also dependent on palmitoylation in a manner similar to Ras (15, 133).
8

Additional examples of palmitoylation-mediated intracellular trafficking are vast and
diverse. Protein folding and assembly requires Calnexin, which localizes to endoplasmic
reticulum-mitochondrial interaction domains and the nucleus through palmitoylation (43, 134).
Neurochondrin, a negative regulator of Ca++/calmodulin activity in neurons, is targeted and
trafficked from endosomes to dendrites via palmitoylation (32). Palmitoylation of Bax, FAS
death receptor, and Lck kinase mediates translocation from the cytosol to the mitochondria to
induce apoptosis (29, 42). Insulin-stimulated GLUT4 translocation to the plasma membrane from
the cytosol is regulated by palmitoylation of the AKT substrate, CLIP-59 (96). Palmitoylation
also ensures wing disc development by regulating the trafficking of the EGFR ligand Spitz to the
basolateral membrane of cells (74). Furthermore, inhibition of GAD65 palmitoylation has been
shown to downregulate the synthesis of GABA, a critical neurotransmitter (77). Sortilin, c-Met,
and SRC kinases are additional examples of proteins requiring palmitoylation for their
intracellular trafficking and activity (24, 92, 135, 136).
Palmitoylation regulates protein activity by bringing interacting partners into close
proximity, and can modulate kinase activity through conformational changes (6, 18, 118). EGFR
is phosphorylated and interacts with signaling effectors on its cytosolic tail, which has been
shown to be palmitoylated. This is thought to sterically hinder phosphorylation, Grb2 binding,
and modulate its association with the plasma membrane in the absence of ligand binding (26, 27).
During glucose uptake in adipocytes, Caveolin2 is phosphorylated by Insulin receptor. Caveolin2
is also palmitoylated under these conditions, and it is thought the crosstalk between
palmitoylation and phosphorylation induces a PI3K/Akt- and ERK- signaling cascade that
promotes adipocyte proliferation and survival (137). FcLR4 is expressed in a subset of B
lymphocytes and must be palmitoylated to be activated by phosphorylation; this in turn may
enhance the activation of its substrate, NF-κβ (45). Palmitoylation inactivates Fat by inhibiting its
9

phosphorylation to regulate imaginal wing disc size by Hippo signaling (138, 139). The
methyltransferase activity and Golgi localization of the transcriptional repressor EZH2 is
dependent on palmitoylation (60). Palmitoylation induces a conformational shift in the C-terminal
tail of the ion channel STREX BK to sequester it at the plasma membrane, which activates the
channel by sterically inhibiting phosphorylation from its negative regulator, Protein Kinase A
(PKA) (35, 37).
Correct protein folding and stability is regulated by crosstalk between ubiquitination and
palmitoylation (4, 6, 14). Palmitoylated inhibitory SMADs are localized to the plasma membrane
to target BMP type I receptors for ubiquitination, and modulate TGF-β/BMP signaling (140).
Palmitoylation of the yeast SNARE protein, TLG1, induces a conformational shift that inhibits
ubiquitination by facilitating endosomal and Golgi retention (141). Palmitoylation is also
necessary for the stability of the Hippo pathway transcription factor, TEAD (142). Degradation of
the anthrax receptor TEM8 is inhibited by palmitoylation, which prevents its targeting to lipid
rafts where it would otherwise be ubiquitinated (143). In the endoplasmic reticulum,
palmitoylation of the Wnt co-receptor LRP6 induces a conformational shift in the receptor which
ensures correct folding of the protein and stability by blocking ubiquitination recognition sites
(68).
These examples highlight an essential role for palmitoylation on maintaining signaling
activity through protein conformation, stability, and binding partner interactions. Extracellular
stimuli may also vary the intracellular distribution of DHHC enzymes and rate of palmitoylation,
which may alter protein activity dynamics (15). Furthermore, localizing various DHHCs enzymes
to distinct cellular compartments may also function as another layer of regulation to modulate
protein trafficking and activity. Examining these protein distributions within tissues may shed
insights on how signaling is disrupted in disease.
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1.6 Palmitoylation function during development
Numerous studies, including the works mentioned thus far, have implicated
palmitoylation as a key spatio-temporal regulator of signaling activity and demonstrate how
altered palmitoylation is a factor in disease progression. Palmitoylation has been implicated as a
critical factor in cell fate determination and differentiation in diverse species from plants to
mammals. Across 31 plant species, DHHC-containing palmitoyl transferases were differentially
expressed during cell growth and proliferation in different tissues at various developmental
stages, even within the same plant (144). DHHC13 is thought to modulate Smad6 activity to
specify ectoderm and mesoderm in zebrafish embryos (65). Palmitoylation has also been
implicated in reproductive development where DHHC7 drives follicle stimulated hormone
signaling in Sertoli cells in the testes, to ensure proper spermatogenesis and fertility (145).
Ovaries expressing a palmitoylation-deficient Dad mutant showed a severe loss in the germline
stem cell compartment and aberrant TGF-β/BMP signaling in D. melanogaster oocytes (140).
DHHC21-mediated palmitoylation of Fyn kinase is required for keratinocyte
differentiation from epidermal stem cells and hair follicle development in mice, and inhibition of
DHHC21 resulted in hair follicles with decreased Wnt signaling suggesting palmitoylation
functions in epithelial homeostasis (25). Additionally, DHHC16 and DHHC5 have been
suggested as critical factors of stem cell homeostasis in vivo and in vitro, where independent
studies found these palmitoyltransferases to modulate the switch between multipotency and
differentiation in neural stem and progenitor cells (63, 86). Palmitoylation of the stem cell
determinant, Poltergeist, is similarly essential to maintain the stem cell compartment in
Arabidopsis roots (66).
Signaling pathways such as Wnt, Notch, Hippo, and EGFR are tightly coordinated during
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embryogenesis to promote cell proliferation and differentiation. Modulating the activity of
signaling pathways promotes organ specification, tissue remodeling, and inhibits aberrant
proliferation in the adult. These examples identify a critical role for palmitoylation in
understanding how signaling events are spatio-temporally regulated in response to ligand
stimulation during embryogenesis and cell fate decisions.

1.7 Palmitoylation during cellular homeostasis and tissue maintenance
Because palmitoylated proteins are expressed in most tissues and play a role in
maintaining homeostasis, any disruptions would be expected to result in developmental defects
and disease. In addition to DHHC21, epithelial and skeletal tissue function is dependent on
DHHC13. Loss of function mutations in DHHC13 are associated with various skin disorders
including alopecia and hypotrichosis in patients. Furthermore, inhibiting DHHC13 activity in
mice results in gross skeletal defects, decreased bone mass, multiple organ failure, osteoporosis,
and amyloidosis (25, 146–148). Studies have shown DHHC7 and DHHC17 maintain glucose
homeostasis in adipocytes in response to insulin signaling, and have identified additional
palmitoylated substrates adipocytes with proteomic screens (95, 96, 149). Regulation of
palmitoylation has also been shown to maintain lipid metabolism in liver and muscle, suggesting
dysregulated palmitoylation may contribute to the development of metabolic disorders such as
insulin resistance, hyperglycemia, and diabetes (95–97, 150, 151).
Gene expression and genomic stability may require palmitoylation, and over a quarter of
palmitoylated mammalian substrates were identified as nuclear proteins (18, 152) . The
transcription factor SNAIL, a known driver of epithelial-to-mesenchymal transition in tumors,
regulates the expression of palmitoyltransferases and depalmitoylating enzymes. As many
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palmitoylated substrates are also involved in cell polarity and tumor development, SNAIL may
also affect the function these proteins at both the transcriptional and post-translational level (121,
153). Palmitoylation of TEAD, a transcription factor of the Hippo pathway, promotes its
interaction with transcriptional co-activators YAP and TAZ to mediate Hippo pathway signaling
during tissue growth and muscle differentiation (101, 142). Lyn kinase, as mentioned earlier, is
palmitoylated in a cell-cycle dependent manner to inhibit its nuclear localization and prevent
chromosomal segregation errors (24). Both loss of DHHC16 and pharmacologic inhibition of
palmitoylation impair DNA damage response in cells by blocking G2/M progression and
inhibiting ATM-p53 signaling (59). In yeast, palmitoylation of the telomere-binding protein Rif1
modulates transcriptional silencing and heterochromatin formation (61). Furthermore, silencing
DHHC8 in radiation-treated mesothelioma cells impairs G2/M progression, and increases
chromosomal instability and apoptosis (62).
In recent years, palmitoylation has been found to play a large part in immune cell fate and
function in adult tissues. A key step in immune cell function is antigen stimulated protein
recruitment to the immune synapse. Similar to neuronal synapses, the polarized recruitment of
many synaptic proteins requires palmitoylation (46). The development of memory B lymphocytes
and T cells is dependent on palmitoylation of the immunomodulatory receptors FcLR4 and LAT,
respectively (45, 48). Interestingly, palmitoylation itself is regulated during periods of anergy
(inactivity) and activation. This is observed with LAT, where its palmitoylation is downregulated
in anergic T cells (47).
Ion-mediated second messenger signaling (calcium- or sodium-mediated) affects the
function of many enzymes, mediates electric impulses, and is essential for cellular homeostasis.
Acute regulation of ion channels and pumps is critical to maintain ion homeostasis and flux to
prevent cellular stress and death (41, 154). Several pumps and channels have been reported to be
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palmitoylated in various tissues including cardiac and skeletal myocytes, fibroblasts, pancreatic
β-cells, and embryonic kidney cells. Additionally, both pharmacologic and genetic perturbation
of palmitoylation may induce mitochondrial dysfunction and cellular stress (35, 36, 39, 40, 100,
155). Senescence and apoptosis prevent the accumulation of damaged cells in healthy tissues, and
studies show evidence of these cellular responses requiring palmitoylation (26, 29, 33, 56, 156)
26,29,33,56,160

.

Extensive studies mentioned in this chapter demonstrate palmitoylation is critical for
neural development and function. Communication between neurons requires the precise
coordination of neurite formation and synaptic communication, two processes that both require
palmitoylation for polarized protein transport as mentioned earlier (157). Dysregulated
palmitoylation is closely associated with the onset of disorders such as Huntington’s disease,
Alzheimer’s, anxiety, learning disorders, and schizophrenia (6, 11). Decreased or complete loss
of DHHC13 and DHHC17 is a major driver of Huntington’s onset and progression (78–80, 158,
159). In addition to maintenance of synapse function, DHHC7, DHC12, and DHHC21 may be
misexpressed in Alzheimer’s patients and have been implicated in preventing amyloid plaques
widely thought to contribute to Alzheimer’s pathogenesis (82, 83, 160). Suppression of DHHC5,
DHHC8, and DHHC13 activity and expression has also been linked to learning/memory defects,
schizophrenia, and anxiety disorders (84, 85, 87, 161).
Surprisingly, the role of depalmitoylating enzymes on homeostasis and disease remains
poorly understood. APT1-knockout male mice display significantly decreased body fat according
to the International Mouse Phenotype Consortium, suggesting APT1 is critical for adipose tissue
development, homeostasis, and endocrine regulation by adipose tissue (IMPC). Both APT1 male
and female knockout mice have also been characterized with behavioral defects (IMPC).
However, the mechanisms by which APT1 maintains behavior and adipose homeostasis remain
14

unknown. Mutations in PPT1 have also been identified and associated with infantile Batten
disease, a debilitating and fatal neurodegenerative disorder (162). Examining palmitoylation with
other posttranslational modifications during cellular processes in normal tissues may uncover
novel regulatory networks for spatiotemporal signaling pathway regulation.

1.8 Palmitoylation function in cancer development
Several DHHC enzymes may demonstrate tumor promoting or tumor suppressor
function, or both, in various cancers. Downregulated expression of DHHC2 has been correlated
with increased liver metastasis and poor prognosis for gastric and colorectal cancers (90, 163).
Silencing DHHC3 expression results in suppressed tumor cell migration and invasion through
decreased Integrin α6β4 palmitoylation, suggesting potential oncogenic function. Conversely,
DHHC3 may also function as a tumor suppressor as its decreased expression was observed in
squamous cell cervical cancer and hepatocellular carcinoma (23, 164, 165). Overexpressed
zHHC5 was reported as a driver of tumor initiation in non-small cell lung cancer cell models, and
has also been linked to increased tumorigenic and self-renewal potential of p53-mutant glioma
cells (60, 166).
The hormone receptors ERα, ERβ, PR, and AR have been identified as substrates of
DHHC7, suggesting DHHC7 activity may contribute to the development of hormone-positive
tumors. Palmitoylation of these receptors facilitates their membrane localization, which has been
associated with enhanced metastasis and tumorigenic potential through nuclear-independent
activity (23, 118, 167). Scribble, a regulator of cell polarity and neuronal synaptic function, is a
membrane-localized tumor suppressor. Its membrane localization is regulated by DHHC7, and is
inhibited by the EMT driver SNAIL, which has been shown to transcriptionally repress
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palmitoylation (53, 153). Future examination of SNAIL on palmitoyltransferase expression may
reveal greater insights on the localization and expression of tumor suppressors and polarity
regulators in the developing embryo, adult tissue, and within tumors. Increased DHHC11
expression has also been associated with aggressive bladder tumors (91). Additionally, DHHC13
may exhibit tumor suppressor function in melanoma and other skin carcinomas (57, 146). High
DHHC14 expression is correlated with poor disease outcomes in gastric cancer patients, and was
found to increase tumor cell invasion and migration (89). Numerous studies have demonstrated
that palmitoylation of CD9, CD44, CD151, Claudin7, and c-Met, require palmitoylation for
metastatic potential (88, 92, 93, 164, 168). Palmitoyltransferases may also be differentially
expressed or serve different functions within the same type of tumor. In breast, ovarian, colorectal
and blood tumors, DHHC9 expression was downregulated while DHHC20 and DHHC21 are
overexpressed (23, 94, 167). DHHC14 and DHHC17 may also function differentially as tumor
suppressors or oncogenic drivers depending on the cancer type (23).
Depalmitoylating enzymes, while less studied, also exhibit differing functions in tumor
development and progression. APT1 is frequently amplified in various human cancers including
prostate, uterine, and breast, and this amplification may correlate with poorer survival outcomes
according to The Cancer Genome Atlas (TCGA). PPT1 is also generally amplified in tumors,
while APT2 and PPT2 is often deleted or mutated (TCGA). Wnt5a stimulates APT1
phosphorylation driving its depalmitoylating activity, and expression of APT1 phosphomimetic
or inactivating mutants implicates APT1 as a regulator of melanoma cell invasion and metastasis,
thus uncovering a role for depalmitoylation in Wnt5a-overexpressing tumors (70, 169).
Protein palmitoylation may also be exploited for therapeutic purposes. For example,
silencing DHHC20 and EGFR palmitoylation deficient mutants increase the sensitivity to EGFR
kinase inhibitors in human triple receptor negative breast cancer cells and in Kras mutant cells
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(26, 170). As mentioned in previous sections, small molecule inhibition of APT1 can disrupt Ras
membrane localization and downregulate signaling. These molecules have been explored as a
therapeutic strategy in suppressing Hras and Nras mutant function, although with variable results
(75, 103, 119, 171). With such a large pool of palmitoylated substrates, identifying bona-fide
substrate-enzyme pairs may uncover greater therapeutic efficacy and specificity to palmitoylated
proteins when designing inhibitors or drug combination treatments (23). This strategy has been
employed to target Ras depalmitoylation is induced upon FKBP12 binding. Pharmacologic
inhibition of FKBP12 was shown to increase amounts of palmitoylated Ras at the plasma
membrane, potentially increasing exposure of the active Ras form to inhibitors (172).
Understanding these enzyme-substrate interactions may also increase our understanding of drug
resistance in recurrent tumors to uncover areas for therapeutic development.

1.9 Palmitoylation establishes and maintains polarity
As mentioned in earlier sections, palmitoylation directs protein polarity within cells and
across multicellular structures to facilitate and maintain responses to signaling pathways.
Pharmacologic inhibition and genetic screens identified palmitoyltransferases necessary for the
formation and growth of polarized root hairs, which are sensory structures in Arabidopsis that
transmit external stimuli (173). The division and growth of fission yeast occurs along a polarized
axis, which promotes membrane growth as the yeast increase in size. Establishment this polarized
axis is dependent on the membrane localization of yeast casein kinase 1γ ortholog, Cki3, which is
driven by palmitoylation, and yeast expressing palmitoylation-deficient Cki3 show a growth
delay (31).
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In D. melanogaster wing discs, Approximated palmitoylates Fat, a negative regulator of
growth that restricts Dachs accumulation at apical junctions to inhibit Hippo signaling(138).
Palmitoylation of Fat negatively regulates its activity, allowing for Dachs accumulation at apical
junction to drive wing growth (138, 139). The association of the discs large homolog, MPP3, and
nectins at apical cell junctions is also dependent on palmitoylation of MPP3; this has also been
shown necessary to set up the polarity of the developing D. melanogaster embryo (174). The
formation and stability of polarized cell junctions is crucial in the maintenance of epithelial
barrier integrity and cell-cell communication (175). Proteins required for cell junction assembly
and maintenance, including PMP22, Plakophilin, JAM3, SNAIL, and Claudin7, maintain their
polarized localization and function through direct palmitoylation (51, 52, 54, 88, 99, 121).
Cytoskeletal regulators and components have also been reported as palmitoylated
substrates. Palmitoylation of tubulin has been shown to be essential for membrane association
during cell division and spindle stability during meiosis in yeast. Whether palmitoylation is also
required for membrane association in non-dividing cells, polarized trafficking, or if its
palmitoylation is regulated in a cell-cycle dependent manner remains to be determined (176–178).
Other small GTPases involved in actin reorganization and vesicular trafficking, such as RhoB,
RAC1, and RAB10, require palmitoylation to localize at membrane compartments (179–181).
Additionally, palmitoylation of the master polarity regulator CDC42 is necessary for proper
dendrite formation and synaptic function in hippocampal neurons (181–183).
As polarity is essential to properly localize signaling components in the developing
embryo and in adults to maintain tissue integrity, it is thought to function as a tumor suppressor
mechanism (184). How palmitoylation establishes these interactions may uncover greater
insights into developmental disease and tumor initiation and progression.
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1.10 Limitations to studying palmitoylated proteins
Palmitoylation was first discovered in 1979, the same year as phosphorylation and four
years after ubiquitination (185–187). Although it is as common as phosphorylation and
ubiquitination, very little is known about the biological impact and function of palmitoylation in
an organism. Detection methods also lag far behind those of phosphorylation and ubiquitination
(188).
Libraries of hundreds of putative palmitoylated substrates have been assembled from
genomic and proteomic screens from diverse species including Drosophila melanogaster,
Caenorhabditis elegans, yeast (Schizosaccharomyces pombe, Cryptococcus neoformans,
Saccharomyces cerevisiae), parasites (Toxoplasma gondii, Plasmodium falciparum), Danio rerio,
Arabidopsis thaliana and mammals (human: prostate cancer cells, B lymphoid cells, endothelial
cells, Jurkat T cells, platelets, rat neurons, and mouse T cell hybridoma cells) (16, 18, 22, 58, 63,
65, 66, 189–192). Although palmitoylated proteins can be detected with high-throughput means
such as mass spectrometry, the hydrophobicity, poor solubility, and poor fragmentation of
palmitoylated proteins has made this approach extremely challenging and prone to false negatives
(188, 193). Furthermore, validating bona-fide palmitoylated substrates from libraries is
predominantly based off generating point mutants and can be an unwieldy endeavor if the number
of palmitoylated cysteines is unknown or if data sets are large (15, 18). In silico approaches, such
as Swiss-palm, CSS-palm, and GPS-lipid, predict putative substrates and palmitoylated residues
based on databases of known palmitoylated sequences (18, 152). Again, the lack of a consensus
sequence can result in false omission or identification, and thus, in silico approaches should be
combined with protein structure analysis and biochemical validation.
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Limitations in protein-based and fluorescence-based have also increased the difficulty of
identifying and validating palmitoylated substrates. Immunoblotting based approaches in cell and
tissue lysates can be used identify changes in global palmitoylation or validate specific substrates
from libraries or in silico methods. When combined with metabolic labeling using azido- or
alkyne-palmitate analogs, this approach can provide insights into relative palmitate turnover.
However, metabolic labeling may not be sensitive enough to detection of proteins with a low
turnover rate, resulting in false reporting as non-palmitoylated (18). Acyl-biotin exchange (ABE)
and variations have also emerged as a reliable and relatively sensitive detection
immunoprecipitation-based assay where the reactive thiol on palmitoylated cysteines is replaced
with a biotin analog (194, 195). Because metabolic labeling is not required in this assay,
substrates can theoretically be detected regardless of palmitate turnover rates. A variation of the
ABE assay, known as the acyl-PEG exchange (APE), can also be used to detect the number of
palmitoylated cysteines on a protein (196). These assays must be rigorously controlled to prevent
reporting of false-positives, as any reactive cysteine can be detected (11, 16, 177).
Another significant setback is the challenge of visualizing the spatio-temporal regulation
of palmitoylated protein localization and turnover in situ. The lack of a defined consensus
sequence has made it difficult to design antibodies to palmitoylated domains (15). Live-imaging
probes have also not yet been designed to examine temporal dynamics of palmitoylation within
cells (18). Early imaging approaches have involved fluorescently tagging palmitoyltransferases,
depalmitoylating enzymes, putative substrates, and corresponding mutants, and imaging
subcellular localization. TIRF and FRAP microscopy techniques may also assess the localization
dynamics of palmitoylated substrates by live-cell microscopy (15). Caveats of these imaging
approaches include an inability to assess is palmitate incorporation in real time, and substrates
may not have been rigorously validated as palmitoylated (15, 102).
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The first successful imaging protocol incorporated metabolic labeling to visualize
palmitoylated protein localize at plasma membrane, at membrane domains near the mitotic
spindle, and at the cytokinetic furrow (115). Advancing this protocol, Gao et. al, utilized this
metabolic labeling approach and combined it with in-situ proximity ligation to detect the
subcellular localization of palmitoylated Wnts, Hedgehog, and tubulin in fixed cells (177).
Although prone to false-positives and requiring rigorous validation, these methods have expanded
our understanding of the spatial organization of palmitoylated effectors.
Development of small molecule inhibitors can interrogate the role of palmitoylation on
protein localization, activity, and protein-protein interactions. 2-bromopalmitate (2-BP) is utilized
as a pan-palmitoyltransferase inhibitor. However, results are inconclusive unless validated with
genetic knockdown or protein mutants as 2-BP exhibits many off-target effects, and may disrupt
lipid homeostasis and metabolism at high concentrations (6). Depalmitoylating enzyme inhibitors
have been more successful in terms of specificity and toxicity. Palmostatin B and Palmostatin M
are common inhibitors to APT1 and APT2, and to a lesser degree, PPT1 and PPT2 (67, 75, 103,
132) 67,75,103,131. Newly identified piperazine amide compounds ML-348 and ML-349 display high
sensitivity and specificity for APT1 and APT2, respectively (171). These compounds have been
employed successfully to examine palmitoylation dynamics in vitro, but not yet used in vivo.
Although there is still a great deal of information missing including structure analysis, crystal
structures for APT1, DHHC15, DHHC17, and DHHC20 have been solved (197–199). This
structural analysis of DHHCs may uncover new functional insights into the regulation of
palmitoylation, and may contribute to the development of specific inhibitors with minimal offtarget effects. Additionally, specific inhibitors may be used better understand the biologic
function, protein interaction, and the dynamic regulation of palmitoylation during development or
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in disease settings (15, 18). These studies open up future work into developing specific small
molecule inhibitors for therapeutic strategies in patients.

1.11 Discussion
While the function and regulation of palmitoylation on normal cellular functions,
development, and disease is still rather unclear, palmitoylation is emerging as an essential
regulatory component of cell signaling. The last few years have seen substantial advances in new
detection protocols and assay sensitivity, and new studies are identifying novel palmitoylated
substrates uncovering greater networks of pathway crosstalk. For example, many signaling
pathways are activated during hair follicle development including Wnt and ERK, and
palmitoylation is known to play a major role in hair follicle formation (25, 148). In addition to
Wnt ligands, the signaling pathway components LRP6 and casein kinase have been shown to be
palmitoylated in the last 15 years (28, 69, 200). How palmitoylation facilitates crosstalk for these
pathways during hair follicle formation has not been explored. Furthermore, whether
palmitoylation coordinates the assembly of the Wnt signaling complex and downstream activity
upon ligand binding in a tissue-dependent context, or even within the same cell, remains an
unanswered but important question. Additionally, palmitoylation remains poorly defined within
many critical developmental signaling pathways, as in the case of Notch, where Numb is the only
component known to be palmitoylated to date (71).
Numerous examples in this chapter discuss how palmitoylation facilitates polarized
protein trafficking between cellular components. Polarity itself is regulated by a complex
signaling network, yet only a few polarity regulators (e.g. CDC42, Scribble, Rac) have been
shown to be palmitoylated (53, 179, 181–183). Palmitoylation of additional polarity components
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such as PAR proteins and atypical PKC is currently unknown. How palmitoylation coordinates
these protein interactions to establish polarity in both development and disease will be vital to
address. The numerous examples in these sections also demonstrate how palmitoylation plays a
prominent, but relatively unexplored role, in disease onset and highlight areas where
palmitoylation can be exploited for therapeutic strategies.
In this dissertation, I identify a function for APT1 and DHHC20 in establishing polarized
protein localization during cell division. I also present a role for APT1 in maintaining gene
signatures and in restricting transcription activity of cell-fate signaling pathways to one daughter
cell. Furthermore, I interrogate how loss of APT1 decreases the self-renewal potential of breast
cancer cells and alters the distribution of tumorigenic cells. With these findings, I present a
molecular mechanism for palmitoylation-mediated of asymmetric cell division and develop a
conceptual framework for the maintenance of tumor cell heterogeneity.
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Figure 1.1 Palmitoylation regulates protein-protein interaction, activity, and stability. (A to
C) Palmitoylation promotes the membrane localization of cytosolic proteins (yellow and green) to
specialized domains (dark blue) to facilitate protein-protein interaction at the membrane (A), can
sequester cytosolic facing domains or receptors and integral membrane proteins (dark yellow) to
inhibit effector (pink) binding (B), and may sterically hinder other posttranslational modifications
such as phosphorylation (red) or ubiquitination (purple) to regulate protein activity and stability
(C).
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Figure 1.2 Schematic of palmitoylation. Addition of palmitate to a protein is catalyzed by the
DHHC class of enzymes localized on endomembrane (e.g. Golgi, endoplasmic reticulum,
vesicles) or on the plasma membrane, which facilitates membrane association. Depalmitoylating
enzymes, such as APT1, localize to the membrane to cleave palmitate from substrates via its
catalytic cleft. This process allows both APT1 and the non-palmitoylated substrate to relocalize to
the cytosol for recycling or degradation. Adapted from Conibear et. al. (9).
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CHAPTER 2: IDENTIFICATION OF PALMITOYLATION ON ASYMMETRIC
PROTEIN SEGREGATION AND TRANSCRIPTIONAL ACTIVITY

From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission
from AAAS.

2.1 Summary:
Asymmetric cell division is a key mechanism of generating and maintaining diverse cell
populations, such as stem cells and differentiated cells. Understanding the mechanisms regulating
the asymmetric localization of cell fate determinants in dividing cells is critical as loss of
asymmetric division has been associated with the improper expansion of cell populations and
altered cell fate, resulting in abnormal tissue function. As discussed in Chapter I, palmitoylation
is a mechanism of localizing proteins to subcellular membrane domains and can regulate signal
transduction activity in the cell. However, the function of palmitoylation has not been examined
in asymmetrically dividing cells. In this Chapter, I show that asymmetric protein localization in
dividing cells is dependent on palmitoylation. Furthermore, I demonstrate how the
depalmitoylating enzyme, APT1, and palmitoyltransferase, DHHC20, affect the asymmetric
expression of transcriptionally regulated GFP reporters between daughter cells. These findings
introduce lipid modification as a regulator of asymmetric cell division.
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2.2 Introduction:
The development of multicellular organisms relies on the ability to generate functionally
diverse tissues and organs from an unspecialized stem cell (201). One mechanism of generating
this cellular heterogeneity is through asymmetric cell division where proteins driving cell
identity, also known as cell-fate determinants, are unequally distributed between two dividing
daughter cells. Stem cells are the best-characterized population that undergoes an asymmetric cell
divisions, producing a self-renewing stem cell and a differentiating daughter cell (5).
To initiate an asymmetric division, cell fate determinants must be localized to the plasma
membrane domains in an orientation perpendicular to the mitotic spindle. This ensures that one
daughter will inherit more cell-fate determinants upon cytokinesis, which activates a downstream
transcriptional program that will establish a distinct identity from the other daughter cell (202–
205) (Fig. 2.1). For example, D. melanogaster neuroblasts divide asymmetrically to produce a
self-renewing neuroblast and a differentiating daughter cell (206, 207). This polarity of cell-fate
determinants may be induced through extrinsic signals from the extracellular environment or
through intrinsic polarity (208). Like developing embryos and normal tissues, cells within tumors
also vary in functions such as proliferation, survival, self-renewal, quiescence, genomic
instability, and therapeutic resistance (209–211). However, the contributors of tumor cell
heterogeneity are not fully understood. Genomic instability, epigenetic alterations, and
microenvironment interactions are major contributors but are not the only factors (212–214).
While asymmetric cell division has been commonly thought to function as a tumor suppressive
mechanism to prevent aberrant stem cell outgrowth (184, 201), its contribution to cellular
heterogeneity later in tumor development is not fully understood.
The Notch and Wnt signaling pathways have been shown to be key drivers of cell
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identity. Numb, an antagonist of Notch, is asymmetrically partitioned to the plasma membrane of
dividing D. melanogaster neuroblasts, and is inherited by the cell fate to differentiate into a
neuron (206, 207, 215–217). In mammalian cells, Numb is asymmetrically partitioned in dividing
mammary epithelial precursors, hematopoietic stem cells, and T-lymphocyte precursors (202,
218, 219). Likewise, β-catenin, a regulator of canonical Wnt and progenitor cell fate, is
asymmetrically localized at the plasma membrane of dividing mouse embryonic stem cells and
C.elegans seam cells, and is excluded from the differentiating daughter cell (204, 220).
How Numb and β-catenin are unequally partitioned and retained at the membrane has
been a major challenge in the field, although several mechanisms have been proposed. Mouse
embryonic stem cells grown in vitro and C. elegans seam cells divide asymmetrically in response
to a localized extracellular Wnt stimulus. This reorients the mitotic spindle so that the daughter
cell closest in proximity to the Wnt signal inherits β-catenin and retains a progenitor fate (220,
221). Likewise, Numb is segregated asymmetrically along an apical-basolateral axis in dividing
D. melanogaster neuroblasts, where the apical cell in contact with the neuroepithelium retains a
progenitor fate, while the basal cell inherits Numb and differentiates (206, 215, 217) (Fig. 2.2 A).
This would suggest that an extracellular cellular signaling gradient could induce the localization
in a concentration-dependent manner to induce an asymmetric division, such as in the stem cell
niche (5, 222, 223). Phosphorylation-induced signal cascade have also been proposed as a
mechanism of asymmetrically segregating proteins in dividing cells. Studies from several groups
have shown that aPKC phosphorylates Numb directly to displace it from the apical membrane.
Additionally, apical aPKC localization is maintained through a negative feedback loop with Lgl,
a target that is phosphorylated by aPKC to restrict Numb to the basolateral domain (215, 224,
225) (Fig. 2.2 B). Partitioning protein degradation machinery between daughter cells has also
been proposed as a mechanism of asymmetrically segregating proteins (203). In the mouse
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embryonic stem cells and in C. elegans seam cells mentioned above, β-catenin asymmetry is
reinforced by the asymmetric segregation of the APC destruction complex (which phosphorylates
β-catenin) in the daughter cell farthest away from the Wnt signal (204, 220)(Fig. 2.2 C). It is
important to note is these mechanisms function together to establish and maintain polarized
protein localization. What remains unclear is how these asymmetric domains of cell fate
determinants are maintained at the plasma membrane over the course of cell division long enough
to result in altered cell fate (Fig. 2.2 D).
Although lipid modifications have been shown in Chapter I to regulate protein polarity
and intracellular localization, the role of lipid modifications on protein localization during
asymmetric cell division has not been studied. Being a reversible lipid modification,
palmitoylation could promote asymmetric membrane association and also allow for interaction
with cytosolic proteins through depalmitoylation (Fig. 2.2 D). Additionally, the role of
asymmetric cell division on tumor cell heterogeneity remains unclear, although palmitoylation
has been shown to be a key regulator of protein localization and activity in cancer as discussed in
Chapter I. Here, I use triple receptor negative breast cancer and osteosarcoma cell lines, derived
from tumors reported to exhibit a high degree of cellular heterogeneity (226–230), as a
biochemically tractable model to interrogate the cell-intrinsic factors that regulate asymmetric
protein localization in dividing cells. I show that not only are Numb and β-catenin asymmetrically
localized in dividing cancer cells, but also this localization is dependent on APT1 and DHHC20.
Furthermore, pharmacologic inhibition of APT1 recapitulates this observation. I also show that
Numb and β-catenin are palmitoylated in cancer cells, and mutation of specific cysteine residues
on Numb decreases both its palmitoylation and asymmetric localization. Finally, I show that
Notch- and Wnt- transcriptional GFP reporters are asymmetrically expressed in daughter cells,
and this asymmetric activation is dependent on APT1 and DHHC20. Together, these results
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provide evidence for a role for palmitoylation-mediated asymmetric cell division, which may
contribute to tumor cell heterogeneity.

2.3 Activity of the depalmitoylating enzyme APT1 is required for asymmetric localization of
proteins
The depalmitoylating enzyme APT1 has been previously shown to promote the transient
and asymmetric localization of cell adhesion molecules during interphase in response to
extracellular signals (70). To test the hypothesis that APT1 directs the asymmetric localization of
Notch and Wnt signaling-associated cell fate determinants, during cell division, I first set up
parameters to score a dividing cell as asymmetric. I examined the spatial organization of Numb,
β-catenin, and the palmitoylated proteins CD44 and RhoB (93, 180, 231, 232) in fixed cells to
determine if asymmetric protein localization was a common trait in dividing cells. Using the
human MDA-MB-231 triple receptor–negative breast cancer cell line, dividing cells were
identified by immunostaining for acetylated tubulin, a marker of stabilized tubulin structures such
as the mitotic spindle and cytokinetic midbody (233), and counterstained for Numb, β-catenin,
CD44, or RhoB. To rule out the possibility of any observed asymmetric protein localization being
the result of intracellular diffusion, I expressed a control GFP plasmid and assessed GFP
localization by immunofluorescence. To assess whether a cell divided asymmetrically or not, I
measured and plotted the percentage difference in the mean fluorescence pixel intensity of the
protein signal across dividing cells with the following equation (Fig. 2.3 A, B):
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Generally, most dividing cells displayed symmetric protein localization in the absence of
exogenous stimuli (Fig. 2.3 B). Individual cells with a percentage difference of 20 or greater were
scored as asymmetric, and the total percentage of asymmetrically dividing cells was plotted
according to the equation below:

β-catenin was asymmetrically localized in 26.1% of cells, Numb in 29.4% of cells, RhoB
in 8.3% of cells, CD44 in 12.2% of cells, and GFP in 8.5% of cells (Fig. 2.3 C-G). Treating cells
with Palmostatin B (PalmB), a pharmacological inhibitor of APT enzymes (234), reduced the
asymmetric localization of Numb by 3.0-fold (29.4% vs. 9.9%) and β-catenin by 3.3-fold (26.1%
vs. 8.0%) (Fig. 2.3 C, D). The percentage of cells with asymmetrically localized GFP, CD44, or
RhoB were not higher than the background percentages observed for β-catenin and Numb
(approximately 8%), and were unaffected by PalmB treatment (fig. 2.3 E-G). These findings
suggest that APT enzymes are required for establishing asymmetric localizations of Numb and βcatenin in dividing cells.

2.4 APT1 and DHHC20 are required for asymmetric Numb and β-catenin localization in
dividing cells
Having shown the asymmetric localization of Numb and β-catenin (Fig. 2.3 A, B) can be
perturbed by inhibiting the activity of depalmitoylating enzymes, I asked whether APT1 was
specifically required. To address this question, I knocked down APT1 with a short hairpin RNA
(shRNA) (Fig. 2.4 c). In APT1 knockdown cells, asymmetric localization of Numb was reduced
by 6-fold (29.4% vs. 4.9%), and asymmetric localization of β-catenin was reduced by 4.1-fold
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(26.1% vs. 6.4%). Ectopic expression of wild-type human APT1 (APT1WT) from a plasmid
restored asymmetric localization of Numb and β-catenin to baseline control conditions (Fig. 2.4
E-H). However, ectopic expression of a catalytically inactive mutant form of APT1, in Ser119 in
the catalytic domain is mutated to Ala (APT1S119A) (132, 235), failed to rescue asymmetric Numb
and β-catenin localization (Fig. 2.4 E-H). This indicates that the catalytic activity of APT1 is
critical for asymmetric Numb and β-catenin localization.
Of the 23 DHHC palmitoyltransferases found in mammalian cells, DHHC20 is one of
three localized to the plasma membrane and is also known to be expressed in MDA-MB-231
cells, where it palmitoylates EGFR and attenuates EGFR signaling (26, 236). Therefore, I would
expect it to be available to palmitoylate targets like Numb and β-catenin. To determine whether
loss of DHHC20 affected protein localization, I knocked down DHHC20 and observed reduced
asymmetric localization of Numb and β-catenin in a manner similar to APT1 knockdown (Fig.
2.4 D-F, I, J).
The dependence of Numb and β-catenin asymmetric localization on APT1 suggests that
Numb and β-catenin may be palmitoylated. To evaluate protein palmitoylation in native cell
conditions, I used acyl-biotin exchange (ABE) assays (194). In the ABE assay, proteins are
treated with N-ethylmaleimide to block free thiol groups, then the Cys-palmitoyl thioester
linkages are cleaved with hydroxylamine (HAM), and the newly exposed thiol groups are coupled
to biotin. The modified proteins are then purified with streptavidin (Fig. 2.5 A). Results of ABE
assays were consistent with Numb and β-catenin being palmitoylated under normal growth
conditions (Fig. 2.5 B, C). Treating cells with PalmB increased the total amounts of palmitoylated
Numb and β-catenin (Fig. 2.5 B, C), indicating that palmitoylation of these proteins was inhibited
in part by APT enzymes. As a negative control, I did not detect palmitoylation of the extracellular
signal–regulated kinase (ERK), which is not known to bepalmitoylated (Fig. 2.5 D).
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Together, these findings uncover a role for APT1, and palmitoylation in general, in the
spatial distribution of the palmitoylated cell fate determinants Numb and β-catenin.

2.5 Asymmetric localization of Numb requires palmitoylation of the phosphotyrosine
binding domain
Although I found β-catenin to be palmitoylated, β-catenin cortical localization is
mediated through association with cadherins at tight junctions (237, 238). However, the necessity
of palmitoylation for the membrane localization of β-catenin is unclear and will be discussed in
later chapter. The conserved phosphotyrosine binding (PTB) domain of Numb is required for
association of Numb with the plasma membrane and for asymmetric localization of Numb in D.
melanogaster through mechanisms that are still unknown (239). I sought to directly test whether
palmitoylation of Numb is required for its asymmetric localization. Using the palmitoylation
prediction algorithm CSS-Palm (240) and through identification of solvent-exposed cysteine
residues within the PTB domain crystal structure (241), three conserved and potentially
palmitoylated cysteine residues (Cys37, Cys160, and Cys165) were identified and mutated to Ala
(Fig. 2.6 A, B). The Numb triple Cys-to-Ala mutant (NumbAAA) showed reduced palmitoylation
as measured by metabolic labeling of cells with palmitic acid azide, which allowed for the study
of palmitate turnover on Numb (Fig. 2.6 C). Endogenous β-catenin was also metabolically
labeled with palmitic acid azide, confirming the efficiency of labeling in all reactions (Fig. 2.6 C).
These results demonstrate that Numb and β-catenin are continuously palmitoylated in MDA-MB231 cells.
Next, I visualized the dynamic localization and segregation of fluorescently labeled Numb
and APT1 during cell division by live-cell imaging. Because MDA-MB-231 cells shifted from a
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flat, spread morphology to a raised, rounded morphology out of the imaging plane during cell
division, I instead utilized U2 OS human osteosarcoma cells, which maintained a consistent
rounded morphology within the imaging plane during division. U2 OS cells were transduced to
stably express a mCherry-Histone B (H2B) plasmid, allowing for the unambiguous identification
of cells undergoing division in real time. Over the course of cell division, cyan fluorescent protein
(CFP)-tagged APT1WT (APT1WT-CFP) and yellow fluorescent protein (YFP)-tagged NumbWT
(NumbWT- YFP) exhibited highly dynamic asymmetric localization (Fig. 2.6 D). At the beginning
of the cell division cycle, NumbWT was concentrated at one end of the cell at the plasma
membrane, but as daughter cells formed, the localization of Numb shifted to membrane regions at
and near the cleavage furrow. Finally, as daughter cells separated, Numb was partitioned to the
plasma membrane of the cell that emerged from the same side of the mother cell to which Numb
was initially concentrated. APT1WT co-segregated with Numb to membrane regions and retained
in daughter cells with high Numb signal as indicated by line-scan analysis of YFP and CFP pixel
intensity along the division axis (Fig. 2.6 D, Movie S1-3, red arrows). This suggests that APT1
either responds to the same spatial cues as Numb. Alternatively, APT1 may direct Numb
localization or vice versa. YFP-tagged NumbAAA (NumbAAA-YFP) was live-imaged to determine
the contribution of Numb palmitoylation on its localization. NumbAAA showed a 1.5-fold reduced
asymmetric localization in dividing cells as compared to NumbWT (Fig. 2.6 E). Finally, knocking
down APT1 reduced asymmetric NumbWT localization but did not further reduce the asymmetry
of NumbAAA (Fig. 2.6 E). These results collectively show that the asymmetric partitioning of
Numb is actively maintained by a mechanism that requires both APT1-mediated depalmitoylation
and palmitoylation of Cys37, Cys160, and/or Cys165 within the PTB domain.
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2.6 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell
One downstream effect of asymmetrically partitioning cell fate determinants during cell
division is the activation of different transcriptional networks in the two daughter cells, resulting
in cells with unique transcriptional profiles (203, 204, 206). I hypothesized that APT1 could also
mediate the partitioning of asymmetric transcriptional activity of the Notch and Wnt-β-catenin
signaling pathways to one daughter cell. I expressed GFP reporter transgenes containing Notchactivated RBPJ (recombination signal binding protein for immunoglobulin kappa J region)
binding sites (pGF1-Notch) (242, 243) or Wnt-activated TCF and Lef1 binding sites (pGF1TCF/Lef1) in MDA-MB-231 cells, which were then immunostained for GFP and acetylated
tubulin in daughter cells (Fig. 2.7 A, B). After plotting the distribution of asymmetric divisions as
described in fig. S1, I observed asymmetric Notch and TCF/Lef1 reporter signal in 22.7% and
31.7% of daughter cells, respectively. A control GFP reporter containing a minimal CMV
promoter (mCMV) lacking pathway-specific promoter elements showed symmetric signal in most
cells and confirmed that the observed asymmetries were dependent on the TCF/Lef1 and Notch
enhancer elements (Fig. 2.7 C, D). Pharmacologically inhibiting APT1 with PalmB treatment
reduced asymmetric Notch reporter signal by 3.1-fold (31.7% vs. 10.2%), and Wnt reporter signal
by 2.6-fold (22.7% vs. 8.7%), respectively (Fig. 2.7 E, F). Knocking down APT1 or DHHC20
also reduced asymmetric Notch and Wnt reporter signal, indicating that palmitoylation can
restrict Notch- and Wnt-dependent transcription to one daughter cell (Fig. 2.7 G, H).
Together these findings suggest palmitoylation may direct the localization of a Wnt
activating factor and a Notch inhibitory factor to restrict transcription to one daughter cell.
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2.7 Discussion
Maintaining a balance between asymmetric and symmetric divisions is essential for
sustaining cell diversity during development and in adult tissues. Asymmetric divisions maintain
the size of cell populations, such as proliferative stem cells and non-dividing differentiated cells,
to generate cellular heterogeneity and carry out minor tissue repairs. Symmetric divisions are
expansive and can generate identical cells when rapid growth is necessary, such as during early
embryogenesis, tissue formation, and large-scale tissue repair after injury. Disruption of
asymmetric cell division can lead to tissue failure, resulting in disease, due to the aberrant
overgrowth of the progenitor population as in the case of acute myeloid leukemia and
neuroblastoma, or may contribute to aging as stem cells lose the ability to self-renew and tissue
repair cannot be carried out. As fate-determinant proteins direct cell identity, regulating the
intracellular distribution of these proteins during cell division is necessary to prevent the
improper expansion of cell populations.
As mentioned in the introduction, several mechanisms have been proposed to regulate
asymmetric cell division including protein-protein interaction, asymmetric partitioning of
degradation machinery, and an extracellular signaling gradient. APT1 was previously shown to
promote the polarized localization of a palmitoylated substrate in response to extracellular stimuli
in melanoma cells (70). However, whether lipid modifications were required for asymmetric
protein localization has not been examined in great detail. Numb has been found by other groups
to be myristoylated, although inhibition of myristoylation did not disrupt asymmetric Numb
localization in neuroblasts (239, 244). Palmitoylated β-catenin was identified in several
palmitoylomes; however, β-catenin palmitoylation remained unconfirmed until recently (60, 71,
121, 245, 246). The results presented here uncover a cell-intrinsic mechanism through which
APT1 and DHHC20 restrict the localization of the cell fate determinants β-catenin and Numb and
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the downstream transcriptional responses to Wnt and Notch signaling to one daughter cell during
cell division. Importantly, by manipulating APT1 activity, I have demonstrated that the
asymmetric activation of Notch and Wnt transcriptional reporters can be altered without
potentially directly affecting the expression of transcription factors or upstream signaling factors.
Furthermore, palmitoylation directly promotes asymmetric Numb localization as point mutations
in conserved cysteine residues in Numb inhibit not only its palmitoylation but also its asymmetric
localization. Because inhibition of palmitoylation reduces the percentage of cells with
asymmetrically localized cell fate determinants, these results suggest it facilitates a controlled,
rather than a stochastic, process.
I found APT1 inhibition did not completely block the asymmetric localization of βcatenin and Numb, as 8% of dividing cells still were asymmetric. This is similar to the percentage
of cells with asymmetrically localized GFP that does not respond to APT1 inhibition, suggesting
palmitoylation is a key contributing factor, but not the sole mechanism, responsible for
asymmetric protein localization. This palmitoylation-independent asymmetric localization could
be the effect of previously reported asymmetric partitioning of machinery that maintains protein
abundance such as the proteasome (203, 247) or protein translation machinery (248, 249), which
could result in localized differences in protein degradation or synthesis during cell division.
Wnt5a has been reported to stimulate APT1 depalmitoylating activity, resulting in polarized
protein localization (70). While the Numb and β-catenin asymmetries shown have occur without
exogenous ligand stimulation, it is possible that palmitoylated proteins may localize
asymmetrically in response to extracellular stimulation in a different cancer setting or in a nontransformed setting. Future studies will address whether palmitoylation-mediated plasma
membrane recruitment is initiated by ligand binding, as well as interplay with other proposed
mechanisms.
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The observation that both decreased palmitoylation of the NumbAAA mutant, or increased
palmitoylation of Numb upon APT1 knockdown, can inhibit asymmetric localization suggests it
is the dynamic, plasma membrane association that promotes asymmetry. Similar to an early study
characterizing palmitoylated protein localization at the cytokinetic midbody (115), I also find
APT1 and Numb localize at the midbody, which implies a factor may serve as a recruitment
platform for palmitoylated proteins. Having shown β-catenin is palmitoylated and asymmetrically
localized, it is possible that its asymmetric localization may require palmitoylation in a mannaer
similar to Numb. Additionally, future studies will uncover whether palmitoylation is necessary
for the stability or activity of Numb or β-catenin, which may affect their intracellular localization
and asymmetric Notch- or Wnt- transcription. Finally, another area of study would be to
determine how these palmitoylation-deficient Numb and β-catenin mutants affect Notch and Wnt
signaling and transcriptional activation.
Palmitoylation is a dynamic process that regulates cell polarity through cycles of
membrane association and dissociation. In addition to gradients, asymmetric degradation
machinery, and phosphorylation cascades, palmitoylation may be another component in that
stabilizes or establishes asymmetric protein localization during division. The data presented here
show a previously unstudied role for palmitoylation on asymmetric cell division and potentially
on cell identity.
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MATERIALS AND METHODS

Cell Culture
MDA-MB-231 and U2OS cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No.
10566-016) and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO
(Sigma; Cat. No. D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in
DMSO, or 5 μM 2-bromopalmitate (Sigma; Cat. No. 21604-1G) prepared in DMSO for 16 hours
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for
selection.

Stable cell lines
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the
following plasmids: Scramble control, GFP-PRRL, APT1WT -CFP-Flag-PRRL, APT1 (S119)CFP-Flag-PRRL, pGF-Notch-mCMV-GFP-puro (System Biosciences; Cat. No. TR020PA-P),
pGF-TCF/Lef-mCMV-GFP-puro (System Biosciences; Cat. No.TR013PA-P), or pGF-mCMVGFP (System Biosciences; Cat. No. TR011PA-1), for 24 hours with LT-1 transfection reagent
(Mirus Bio. Cat. MIR2300). The aforementioned APT1 plasmids were designed with short
hairpin resistant sequences for rescue studies. Virus was collected 72 hours after infection with
0.5-1mL virus used for stable cell line generation. U2OS cells were infected with APT1WT -CFPFLAG or APT1(S119)-CFP-FLAG lentivirus for 24 hours, then recovered in complete DMEM
for 48 hours prior to cell cultureMDA-MB-231 were infected with the aforementioned lentivirus
for 24 hours and recovered in complete DMEM for 48 hours prior to cell culture.

Short hairpin design
shRNA for APT1
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F 5’CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’
R 5’AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘

Alignment of Numb
Numb sequences from D. melanogaster (P16554), M. musculus (Q9QZS3), D. rerio (Q5FBC1),
and H. sapiens (P49757) were chosen from UniProt canonical sequences. Alignment was
performed with Clustal Omega. Conserved domains were identified by the Conserved Domain
Database (NCBI).

Mutagenesis
Site-directed mutagenesis of Numb C37, C160, and C165 to alanine, and APT1 S119 to alanine
were performed using QuikChange multisite-directed mutagenesis kit (Agilent; Cat. No. 210515).
Potential palmitoylated cysteines on Numb were identified using CSS-Palm 3.0 developed by
Zhou. et. al. (240) and analysis of the PTB domain crystal structure. Mutants were sequence
verified by the DNA Sequencing Facility at the Perelman School of Medicine, University of
Pennsylvania.

Live-cell imaging
MDA-MB-231 cells were not conducive to studying the dynamics of asymmetric localization at
the plasma membrane by live-imaging, as these cells frequently divided out of the focal imaging
plane. Thus, U2 OS cells stably expressing mCherry-Histone H2B facilitated protein tracking
over time and allowed for the study of the dynamics of asymmetric localization at the plasma
membrane over the course of cell division. U2 OS cells stably expressing APT1WT -CFP-FLAGPRRL or APT1S119A-CFP-FLAG-PRRL were transfected with 2 μg of NUMBWT-YFP-FLAG40

PRRL or NUMBAAA-YFP-FLAG- PRRL for 24 hours using LT-1 (Mirus Bio; Cat. No.
MIR2300) according to manufacturer’s protocol. Cells were imaged 48 hours after transfection in
HBSS (Life Technologies; Cat. No. 14175079) containing 2% fetal bovine serum, 1 mg/mL
glutamine, and 20mM HEPES pH 7.4 at 37oC. Cells were imaged using the Leica DMI6000 B
inverted microscope.

Immunofluorescence
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in
primary antibody (β-catenin (9581S; 1:500), CD44 (3570S; 1:500) Cell Signaling Technologies),
(Numb (ab14140; 1:500)/ APT1 (ab91606; 1:500)/ GFP (ab290; 1:500)/ Caveolin (ab17052;
1:500), Abcam), (DHHC20, Sigma; Cat. No. HPA014483; 1:500), (Acetylated tubulin (sc23950),
RhoB (sc-8048), Santa Cruz), 1:1000), for 1-2 hours at room temperature, incubated in secondary
antibody (Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012),
Life Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount
(Southern Biotech; Cat. No. 0100-20). Cells were imaged using the Leica DMI6000 B inverted
microscope on 40X magnification and colonies were imaged on 20X magnification.

Western Blotting
200,000 MDA-MB-231 cells were plated on 60mm tissue culture dishes and were lysed in Tris
lysis buffer (50mM Tris pH 7.4 buffer, 150mM NaCl, 2% Triton-X, 1μg/ml leupeptin, 1μg/ml
aprotinin, 2μg/ml pepstatin A). Proteins were run out on 10% acrylamide gel and probed with
Flag 1:500 (Sigma; Cat. No. F3165), APT1 1:500, Numb 1:1000; β-catenin 1:1000; and DHHC20
1:1000, at 4ºC, overnight, then incubated in secondary anti-rabbit HRP (Jackson
Immunoresearch; Cat. No. 211-032-171) or anti-mouse HRP (Jackson Immunoresearch; Cat. No.
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115-035-003) for 1 hour at room temperature. Blots were developed in Pierce ECL
Chemilluminescence solution (Thermo Fisher; Cat. No. 32106).

Acyl-Biotin Exchange (ABE) Assay
The protocol is adapted from Wan et al., 2007 (194) : 200,000 MDA-MB-231 cells were plated
on 60mm tissue culture dishes and were harvested by scraping in ABE lysis buffer (50mM
HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 5mM EDTA, 50mM N-ethyl-maleimide
(NEM), 1μg/ml leupeptin, 1μg/ml aprotinin, 2μg/ml pepstatin A). Lysates were clarified by
centrifugation at 15,000 RPM for 10 minutes, and incubated with NEM overnight at 4ºC. The
samples were m/c precipitated twice then resuspended in 80μL 4%SDS buffer. The samples were
split in half and 160μL of hydroxylamine buffer (0.7M hydroxylamine pH 7.4, 50mM HEPES pH
7.4, 0.2% Triton X-100, 150mM NaCl, 5M EDTA) was added to one half of the sample and
control 0.2% Triton X-100 buffer (50mM HEPES pH 7.4, 0.2% Triton X-100, 150mM NaCl,
5mM EDTA) was added to the remaining sample and incubated at room temperature for 1hour.
The samples were m/c precipitated and resuspended in 40μL4%SDS buffer containing 10μM
Biotin-HPDP (Thermo Fisher; Cat. No. 21341). 160μLof 0.2% Triton X-100 buffer +10μM
Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c precipitated and
resuspended in 20μL of 4%SDS buffer followed by addition of 800μL of 1% Triton X-100 buffer
(50μL removed for analysis as “input”). 30μL of streptavidin agarose buffer (50mM HEPES pH
7.4, 0.2% Triton X-100, 150mM NaCl, 5mM EDTA) was added to the remaining sample and
incubated at room temperature for 1hour. The samples were m/c precipitated and resuspended in
40μL 4%SDS buffer containing 10μM Biotin-HPDP (Pierce). 160μL of 0.2% Triton X-100 buffer
+10μM Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c
precipitated and resuspended in 20μLof 4% SDS buffer followed by addition of 800μL of 1%
Triton X-100 buffer (50μLremoved for analysis as “input”). 30μLof streptavidin agarose beads
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(Thermo Scientific; Cat. No. 20349) were added to the samples and incubated 20 overnight at 4ºC
rotating. The samples were washed in 1% Triton-X100 buffer and analyzed by SDS PAGE.

Click Chemistry Assay for Palmitoylation
200,000 U2 OS cells were plated on 60mm tissue culture dishes and were transfected with 2μg
Numb WT or NumbAAA YFP-FLAG for 24 hours, labeled with 100μM palmitic acid azide (Life
Technologies; Cat. No. C10265). Cells were prepared using the Click-IT protein reaction buffer
(Life Technologies; Cat. No. C10276) according to manufacturer’s protocol and analyzed with
Western blot as described above.

Quantification and linescan analysis
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in
Fig. S1A. The distribution of acquired percentage differences for each experimental condition
were plotted as dot plots. Cells with a percentage difference of 20 or greater were counted as
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ
software.
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Figure 2.1 Schematic of asymmetric cell division. Establishment of intrinsic polarity (green) is
one of the first steps that must occur for an asymmetric division. Cell fate determinants (red) are
segregated and aligned perpendicular to the mitotic spindle. Upon cytokinesis, fate determinants
are unequally inherited by one daughter cell. This unequal partitioning differentially activates
transcriptional programs, resulting in non-identically fated daughter cells. Adapted from Congdon
et. al. (250).
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Figure 2.2 Reported mechanisms of asymmetric cell division to generate non-identical
daughter cells. (A) Within a stem cell niche, binding of extracellular ligands (yellow) may
induce mitotic spindle rearrangement and asymmetric recruitment of cell fate determinants (red)
along the division axis. (B) Phosphorylation-induced inhibitory signaling (green) may restrict the
asymmetric localization of cell fate determinants (red) to the opposite membrane through intrinsic
mechanisms or extracellular stimuli. (C) Asymmetric inheritance of proteosome components
(blue) may also induce the degradation of cell fate determinants upon cytokinesis. (D) In spite of
this evidence, the mechanisms driving the asymmetric targeting and localization of cell fate
determinants to the plasma membrane during cell division remain unclear. Adapted from
Knoblich et. al. (201).
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Figure 2.3 Scoring method for determining asymmetric divisions. (A) Images of dividing
MDA-MB-231 cells stained for β-catenin, Numb, RhoB, CD44, or GFP (red), acetylated tubulin
(green), and nuclei (blue). Regions of interests (ROI), outlined in white dotted line, were obtained
by drawing around each spindle pole or daughter cell in the image. The mean grey values
generated from each ROI were used to calculate the percentage difference, which was obtained
by dividing the difference in ROI values by the average of the ROI values and multiplying by
100. Scale bars, 15μm. (B) Distribution dot plots showing the difference in mean fluorescence
pixel intensity of β-catenin (blue), Numb (red), RhoB (green), CD44 (magenta), or GFP (in cells
expressing an empty GFP vector; yellow) across dividing MDA-MB-231 cells treated with
PalmB (lighter color) or DMSO (saturated color). The distribution of the percentage differences
of all quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored
as asymmetric. n = 106-123 cells scored for each experimental group. Each dot represents a
single cell. (C to G) Quantification of dividing MDA-MB-231 cells showing asymmetric β46

catenin (C), Numb (D), RhoB (E), CD44 (F), or GFP (G) localization after treatment with PalmB
or DMSO control. *P < 0.05, t test. Error bars indicate standard deviation (SD).
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Figure 2.4 Asymmetric Numb and β-catenin localization is dependent on APT1 and
DHHC20. (A and B) Images of dividing MDA-MB-231 cells stained to show endogenous Numb
(A) and β-catenin (B) in red, acetylated tubulin in green, and nuclei in blue. Arrowheads indicate
asymmetric localization of Numb and β-catenin. Scale bars, 15 μm. (C) Immunoblot of MDAMB-231 cell lysates showing knockdown of endogenous APT1 by shAPT1. Wild-type APT1
(APT1WT-CFP-FLAG) or a catalytically inactive APT1 mutant (APT1S119A-CFP-FLAG) were coexpressed with the shRNA for APT1 rescue experiments. Cells expressing a scrambled (Scr)
shRNA sequence were used as a negative control for APT1 knockdown, and cells expressing the
empty vector were used as the negative control for the APT1 rescue experiments. (D)
Immunoblot of MDA-MB-231 cell lysates when DHHC20 was knocked down with shDHHC20.
Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control for
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DHHC20 knockdown. (E and F) Distribution dot plots showing the difference in mean
fluorescence pixel intensity of endogenous Numb (E) and β-catenin (F) across dividing MDAMB-231 cells. The distribution of the percentage differences of all quantified cells
was plotted, and cells with a difference of >20% (black dotted line) were scored as asymmetric. n
= 508–to 582 cells scored for each experimental group. Each dot represents a single cell.
Asterisks indicate statistically significant differences between the indicated groups. (G and H)
Quantification of the number of dividing MDA-MB-231cells showing asymmetric Numb (G) and
β-catenin (H) localization when APT1 was knocked down with shAPT1, and when wild-type
APT1 (APT1WT) or the catalytically inactive APT1S119A mutant was coexpressed with shAPT1.
Cells expressing a scrambled (Scr) short hairpin RNA (shRNA) sequence were used as a negative
control for APT1 knockdown, and cells expressing the empty vector were used as a negative
control for the APT1 rescue experiments. (I and J) Quantification of the number of dividing
MDA-MB-231 cells showing asymmetric Numb (I) and β-catenin (J) localization when DHHC20
was knocked down with shDHHC20. *P < 0.05, **P < 0.01, ***P < 0.001 analysis of variance
(ANOVA) (E to H) or t test (I and J). Error bars indicate SD.
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Figure 2.5 Numb and β -catenin are palmitoylated in MDA-MB-231 cells.
(A) Schematic representation of the ABE assay. Cell lysates are treated with N-ethylmaleimide
to block free thiol groups. Then, the Cysteine-palmitoyl thioester linkages are cleaved with
hydroxylamine (HAM), and the newly exposed thiol groups are coupled to biotin. The modified
proteins are then purified with streptavidin and analyzed by Western blotting. (B to D)
Immunoblots showing biotin-labeled Numb (B), β -catenin (C), and ERK (D) in MDA-MB-231
cell lysates after acyl-biotin exchange (ABE) assays and pulldown on streptavidin beads (PD).
Cells were grown in the presence of either PalmB or vehicle control (DMSO). Input lanes show
cell lysates before pulldown. Samples without hydroxylamine (−HAM) were negative controls
for the ABE reactions.
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Figure 2.6 Palmitoylation and APT1 activity drive Numb localization. (A) Sequence
comparison of the N terminus of Numb from fruit fly (Drosophila melanogaster), zebrafish
(Danio rerio), mouse (Mus musculus), and human (Homo sapiens). The phosphotyrosine domain
(PTB) is highlighted in green, and the putative palmitoylated cysteines are highlighted in yellow.
Conserved residues are indicated by an asterisk (*). (B) Crystal structure of the D. melanogaster
Numb PTB domain indicating putative palmitoylated residues C37, C160, and C165 in yellow.
(C) Immunoblot showing transgenically expressed wild-type Numb (NumbWT) or the NumbAAA
mutant and endogenous β-catenin in U2 OS cell lysates after purification of palmitoylated
proteins. Cells were metabolically labeled with palmitic acid azide or treated with DMSO
(vehicle control), and then lysates were subjected to click chemistry to convert the palmitic acid
moiety to biotin, pulled down on streptavidin beads, and used for immunoblotting. Input was
taken from cell lysates before pulldown. (D) Time-lapse images of dividing U2 OS cells
coexpressing NumbWT-YFP (yellow), APT1WT-CFP (blue), and mCherry–Histone H2B (red).
Fluorescence pixel intensity was measured along the division axis (dashed line), and the
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corresponding pixel values of Numb (yellow line) and APT1 (blue line) along the division axis
were plotted on graphs. Red arrowheads on images and graphs indicate the peak Numb and APT1
pixel intensity at the membrane or cytokinetic midbody. Time is shown in minutes (min). a.u.,
arbitrary units. Scale bars, 15 µm. (E) Quantification of the number of dividing U2 OS cells
showing asymmetric localization of NumbWT-YFP (black bar) and NumbAAA-YFP (gray bar)
when each was coexpressed with shAPT1. Cells expressing a scrambled (Scr) shRNA sequence
were used as a negative control for APT1 knockdown. **P < 0.01, t test and ANOVA. Error bars
indicate SD.
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Figure 2.7 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell. (A
and B) Images of cytokinetic MDA-MB-231 cells stained to show the expression of the pGF1Notch GFP reporter (A) or pGF-1 TCF/Lef1 GFP reporter (B) (red), acetylated tubulin (green),
and nuclei (blue). Arrowheads indicate asymmetric localization. Scale bars, 15 µm. (C and D)
Distribution dot plots showing the difference in mean fluorescence pixel intensity of pGF1-Notch
reporter (C) or pGF1-TCF/Lef1 reporter (D) across dividing cells. Cells expressing an empty
pGF1-mCMV GFP reporter were used as a negative control for the reporters. The distribution of
the percentage differences of all quantified cells was plotted, and cells with a difference of >20%
(dotted line) were scored as asymmetric. n = 784 to 822 cells scored for each experimental group.
Each dot represents a single cell. Asterisks indicate statistically significant differences between
the indicated groups. (E and F) Quantification of dividing MDA-MB 231 cells showing
asymmetric localization of pGF1-Notch GFP reporter (E) or pGF1-TCF/Lef1 GFP reporter (F)
(black bars) after treatment with PalmB or DMSO vehicle control. Cells expressing an empty
pGF1-mCMV reporter (gray bars) were used as a negative control for reporter expression. (G
and H) Quantification of the number of dividing MDA-MB-231 cells showing asymmetric
53

localization of the pGF1-Notch GFP reporter (G) or pGF1-TCF/Lef1 GFP reporter (H) (black
bars) when coexpressed with shAPT1, and shDHHC20. Cells expressing an empty pGF1-mCMV
GFP reporter (gray bars) were used as a negative control for reporter expression, and cells
expressing a scrambled (Scr) shRNA sequence were used as a negative control for knockdown.
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, t test (between reporters and pGF1mCMV) or ANOVA (C to H). Error bars indicate SD.
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CHAPTER 3: HOW DOES PALMITOYLATION ESTABLISH PROTEIN POLARITY ?
From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission
from AAAS.

3.1 Summary
In Chapter II, I have shown that polarized protein localization is dependent on
palmitoylation. Several outstanding questions that arise are: 1) what are the factors, if any, that
may be asymmetrically recruiting Numb and β-catenin to the plasma membrane, and 2) are
palmitoylation components, e.g. substrates and enzymes, interacting with known polarityestablishing machinery in cell to maintain these polarized domains? To address the first question,
I show palmitoylated proteins are localized within close proximity of APT1 and DHHC20. I also
demonstrate that total palmitoylated proteins are asymmetrically localized and inhibition of APT1
alters the spatial distribution of palmitoylated proteins within a dividing cell. To determine how
this palmitoylation-induced polarity is established, I examine how the polarity complex, namely
CDC42, affects the localization of APT1, Numb, and β-catenin as well as transcription outputs
between daughter cells. Together, these data provide mechanistic insight into how palmitoylation
interacts with known cellular machinery to regulate cell polarity.

3.2 Introduction
Polarity is the unequal distribution of cellular components within a cell, e.g. proteins,
mRNA transcripts, vesicles, and organelles (251). This allows the cell to form specialized
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domains, often at the plasma membrane, which can drive processes such as apical-basolateral
domain specification, directed cell migration, synapse formation, vesicular trafficking, and
asymmetric cell division (252, 253). Mechanisms, such as positive feedback loops and directed
protein trafficking, nucleate molecularly distinct domains at the plasma membrane and regulate
the rate of protein-membrane association and dissociation to maintain these domains over time (7,
8, 254) (Fig. 3.1). What remain unclear are the mechanisms that target and maintain protein
localization to the plasma membrane. As reviewed in Chapter I, substrates can be palmitoylated
at and trafficked from the Golgi to intracellular domains, but can also be palmitoylated locally at
molecularly distinct membrane domains (113, 114, 236). Thus, palmitoylation may a potential
mechanism to nucleate protein polarity at the plasma membrane. However, whether additional
mechanisms interact with palmitoylation to maintain these polarized domains is not fully
explored.
CDC42 is a central regulator of several signaling pathways necessary to establish and
maintain polarity, including spatially reorganizing actin and microtubules to direct the trafficking
and fusion of vesicles with the plasma membrane (255–259). Together with Par3, Par6, and
aPKC, CDC42 has also been implicated in driving asymmetric divisions of the C. elegans zygote,
D. melanogaster neuroblasts, and budding yeast (1, 260–263). A member of the Ras superfamily
of small GTPases, CDC42 activity and function is spatially and temporally regulated by cycles of
GTP hydrolysis and GDP exchange (255, 264, 265). When active, CDC42 is able to bind and
traffic substrates from the Golgi to the membrane, which are released when GTP is hydrolyzed to
GDP (264, 266, 267). Extensive studies have shown that disrupting this GTP/GDP exchange
results in lost of cell polarity (264–266). Thus, cycling between and active and inactive state is
critical for CDC42 to nucleate and maintain spatially discrete protein domains at the membrane.
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CDC42 localization and function is also regulated by lipid modifications (181). CDC42
has two alternatively spliced exons that result in a prenylated or palmitoylated isoform (182, 183).
Although, prenylated CDC42 has been conventionally accepted as the widely expressed isoform,
recent studies are discovering expression of palmitoylated CDC42 in various cell types from
platelets, T-lymphocytes, and transformed cell lines (121, 190, 191, 246, 268). Like the
prenylated isoform, palmitoylated CDC42 regulates substrate trafficking between intracellular
compartments and the plasma membrane; however, the function of palmitoylated CDC42 has
only been studied during dendrite formation in neurons (183). It is currently unclear if
palmitoylated CDC42 targets are different from prenylated CDC42, and if the two isoforms
function redundantly. Additionally, while DHHC8 was shown to palmitoylate CDC42 (85, 269),
interactions with depalmitoylating enzymes have not been fully explored.
The localization of palmitoylation cycle components, e.g. DHHCs, APT1, lipid rafts, and
palmitoylated proteins, may offer insights into how cell-fate determinants are asymmetrically
localized in dividing cells. Several studies have shown DHHC enzymes are differentially
expressed and localized within the cell; these differentially localized palmitoyltransferases are
thought to establish spatially distinct membrane domains by maintaining local palmitoylation
cycles (15, 113, 114). APT1 is a primarily cytosolic protein that is recruited to the membrane to
depalmitoylate substrates in an unclear mechanism (19, 132). In this study, I find APT1 activity is
required for its own asymmetric localization and the asymmetric localization of total
palmitoylated proteins in dividing cells. Furthermore, APT1 is observed to localize at membrane
domains enriched in DHHC20 and palmitoylated proteins. Whether palmitoylation-rich domains
are established by CDC42 is also poorly defined. Here, I examine the role of CDC42 activity and
palmitoylation on asymmetric APT1, Numb, and β-catenin localization. With this chapter, I

57

present a mechanism where CDC42 and APT1 function together to nucleate and maintain
asymmetric protein localization in dividing cells.

3.3 Asymmetric localization of APT1 during cell division requires APT1 catalytic activity
Having determined that APT1 activity is essential for asymmetric localization of Numb
and β-catenin, I next examined whether the catalytic activity of APT1 is required for its own
asymmetric localization. Immunostaining fixed cells showed that endogenous APT1 was
asymmetrically localized in 22.3% of control cells. Expressing the catalytically inactive form
APT1S119A reduced this asymmetric localization by 2.4-fold to 9.4%, whereas expressing APT1WT
had no significant effect (Fig. 3.2 A-C). Knocking down DHHC20 also reduced asymmetric
APT1 partitioning, suggesting that DHHC20 promotes asymmetric localization of APT1 (Fig. 3.2
B, D).
To gain detailed insights into how APT1 activity promotes and maintains the dynamics of
its own asymmetric localization, I compared the spatiotemporal distribution of ectopically
expressed APT1WT-CFP versus APT1S119A-CFP by live-cell imaging in wild-type U2 OS cells. In
52.6% of dividing cells, APT1WT-CFP asymmetry was maintained at the plasma membrane
through cytokinesis (Fig. 3.2 E, G; Movies S4-5). The asymmetric localization of APT1S119A-CFP
was significantly reduced to 20.6% of cells, similar to the asymmetric localization of GFP-vector
(16.9%) (Fig. 3.2 F, G; Movies S6-7). Additionally, the catalytically inactive mutant APT1S119ACFP was not discretely localized to the plasma membrane at the start of division and appeared to
be stuck at the cytokinetic midbody during cytokinesis (Fig. 3.2 F, Movie S6-7). The data up to
this point demonstrate that asymmetric localization of APT1 requires its catalytic activity and
suggest a role for protein depalmitoylation activity at the site of asymmetric protein localization.
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3.4 Palmitoylating and depalmitoylating enzymes localize asymmetrically with
palmitoylated proteins during cell division
To clarify the purpose of APT1 accumulation at sites of asymmetrically localized
proteins, I hypothesized that APT1 localizes to regions of high protein palmitoylation. Fixed
MDA-MB-231 cells were immunostained for Numb and β-catenin, which were asymmetrically
partitioned to the same region of a dividing cell as APT1. DHHC20 also displayed asymmetric
localization to the same membrane region as APT1 (Fig. 3.3 A). Additionally, the distribution of
APT1 and DHHC20 overlapped with that of caveolin, a palmitoylated protein (270) and lipid raft
component, at the plasma membrane (Fig. 3.3 B). The results up to this point suggest DHHC20mediated palmitoylation of substrates could recruit APT1 to the membrane.
The presence of both the depalmitoylating enzyme APT1 and palmitoylating enzyme
DHHC20 in plasma membrane–associated domains led me to test whether these regions were
also enriched for palmitoylated proteins. Because there are currently no palmitoylation-specific
antibodies to visualize the localization of palmitoylated proteins, I modified the ABE assay for
immunofluorescence and detected asymmetric localization of total palmitoylated proteins, which
were labeled with biotin, at the cortex of dividing cells (Fig. 3.4 A). This asymmetric localization
depended on the activity of APT1, as PalmB treatment decreased the enrichment of palmitoylated
proteins at the cortex and reduced the percentage of cells showing asymmetric localization of
palmitoylated proteins by 4.1-fold (31.4% vs. 7.6%). The immunofluorescence signal generated
by the modified ABE assay was confirmed to be specific to palmitoylated proteins; negative
control staining of samples in which HAM was omitted from the ABE reaction showed greatly
reduced signal and symmetric localization (Fig. 3.5 B, C). To determine the localization of
palmitoylated proteins relative to APT1 and DHHC20 and whether this asymmetric localization
was only observed during mitosis, I performed the modified ABE immunofluorescence assay on
59

non-dividing cells. Both APT1 and DHHC20 puncta were localized to regions enriched in
palmitoylated proteins at membrane ruffles as assessed by confocal microscopy (Fig. 3.5 A, B).
The data thus far indicate that both APT1 and DHHC20 localize to regions enriched in
palmitoylated proteins, potentially to establish a local palmitoylation cycle.

3.5 A constitutively active CDC42 mutant promotes asymmetric localization of APT1,
Numb, and β-catenin during cell division
I next examined whether APT1-mediated asymmetric protein partitioning functions
independently of known polarity-establishing mechanisms. The Par-aPKC-CDC42 polarity
complex promotes the asymmetric cell division in budding yeast, the C. elegans embryo, and in
D. melanogaster neuroblasts (215, 260, 271). CDC42 and PARD3 (the mammalian homolog of
Par3) were knocked down to assess the requirement of these factors for APT1, Numb, and βcatenin localization (Fig. 3.6 A, B). Asymmetric localization of endogenous APT1 was reduced
by 2.6-fold (22.3% vs. 8.5%) in CDC42 knockdown cells, and by 4.3-fold (22.3% vs. 5.2%) in
PARD3 knockdown cells (Fig. 3.6 C, D). PARD3 knockdown reduced the asymmetric
localization of β-catenin, but not that of Numb (Fig. 3.6 E-H). I next asked if CDC42 and APT1
double knockdown would completely abolish asymmetric Numb and β-catenin partitioning. The
percentage of cells showing asymmetric partitioning of Numb and β-catenin in the double
knockdown condition did not further decrease as compared to APT1 or CDC42 single
knockdown (Fig. 3.6 E-H). This suggests there might be a basal level of asymmetric distribution
for both of these proteins that is independent of both APT1 and CDC42.
I next investigated whether APT1 asymmetric localization depended on CDC42 by
altering CDC42 activity. In its active GTP-bound state, CDC42 is able to bind substrates and
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traffic them to the membrane. Once inactivated through GTP hydrolysis, CDC42 is disengaged
from substrates and released into the cytosol (255, 264, 265). Work from other groups has shown
that expression of either GTP-locked or GDP-locked mutant forms of CDC42 can interfere with
CDC42-dependent cellular processes (1, 255, 258, 264–266). I employed live-cell imaging of
APT1WT-CFP and YFP-tagged CDC42 mutants to test the function of CDC42 activity on APT1
localization. Cells expressing a GTP-locked, constitutively active CDC42 mutant (CDC42V12) or
a GDP-locked, inactive CDC42 mutant (CDC42N17) showed reduced asymmetry of APT1WT
during cell division as compared to cells expressing a control GFP vector (Fig. 3.7 A, B). In fixed
cells, knocking down CDC42 and expressing shRNA-resistant CDC42V12 or CDC42N17 also
significantly reduced asymmetric APT1 and β-catenin localization (Fig. 3.7 C, D, F, H).
Compared to CDC42 knockdown, which had minimal effect, expressing CDC42V12 or CDC42N17
resulted in a strong reduction of asymmetric Numb localization (Fig. 3.7 E, G).
To demonstrate the requirement of CDC42 cycling activity on APT1 localization in cells,
I expressed a YFP-tagged constitutively active CDC42 mutant that retains GTP-GDP cycling
(CDC42F28L). Previously shown by other groups to mimic CDC42-mediated effector binding and
subcellular localization (266), CDC42F28L increase asymmetric APT1WT localization by 1.3-fold
(52.6% vs. 67.0%) (Fig. 3.7 B). Expressing shRNA-resistant CDC42F28L in CDC42 knockdown
cells was sufficient to rescue β-catenin and APT1 asymmetric localization, but only partially
rescued asymmetric Numb localization in CDC42 knockdown cells (Fig 3.7 C-H). Additionally,
expression of CDC42V12, CDC42N17, or CDC42F28L did not significantly alter the low percentage
of asymmetrically localized catalytically inactive APT1S119A as compared to APT1WT by live-cell
imaging (Fig. 3.7 B). These results demonstrate a requirement for the polarity complex and,
specifically, CDC42 activity in promoting the asymmetric partitioning of APT1 and β-catenin to
the membrane. However, although Numb asymmetric localization required CDC42 activity,
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overall it appears to be less dependent than APT1 and β-catenin on the canonical Par-aPKCCDC42 polarity complex.

3.6 The reciprocal interaction between APT1 and palmitoylated CDC42 is sufficient to
promote asymmetric protein partitioning during cell division
In addition to cycling between GTP and GDP, CDC42 function is also maintained in part
by membrane association though a polybasic region and lipid modification of the C-terminal tail
(255, 258). There are two known naturally occurring exon splice variants of CDC42 with distinct
lipid modifications– a solely prenylated splice variant and a dually palmitoylated and prenylated
splice variant (182). I asked whether either CDC42 splice variant could rescue asymmetric
protein localization in CDC42 knockdown cells during division by expressing shRNA-resistant
constructs of the dually lipid modified isoform (CDC42Palm) or the solely prenylated CDC42
(CDC42Pren) splice variants (Fig. 3.8 A) and examining the localization of Numb, β-catenin, and
APT1 in fixed cells. In CDC42 knockdown cells, expressing CDC42Palm was sufficient to fully
rescue APT1 asymmetry, whereas expression of CDC42Pren appeared to inhibit asymmetric APT1
localization (Fig. 3.8 A, D). CDC42Palm and CDC42Pren had little effect on asymmetric Numb
localization in CDC42 knockdown cells. CDC42Palm rescued asymmetric β-catenin localization to
baseline control conditions, but CDC42Pren had no observable effect (Fig. 3.8 B, C, E, F). These
results suggest that palmitoylated CDC42 promotes asymmetric localization of specific
downstream proteins, and APT1 may reciprocally promote asymmetric localization of
palmitoylated CDC42 during cell division.
To spatiotemporally visualize CDC42 and APT1 localization during cell division, I
measured the distribution of APT1WT-CFP and CDC42Pren-YFP or CDC42Palm-YFP by live-cell
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imaging. CDC42Palm expression increased the percentage of asymmetric APT1WT-CFP in dividing
cells by 1.5-fold (52.6% vs. 82.7%) whereas CDC42Pren suppressed asymmetric partitioning of
APT1WT-CFP by 1.9-fold (52.6% vs. 27.2%). In contrast, neither isoform sufficiently altered
asymmetric partitioning of catalytically inactive APT1S119A (Fig. 3.9 A). This led me to ask
whether APT1 was sufficient to promote asymmetric CDC42Palm localization. Both APT1WT-CFP
and CDC42Palm-YFP were asymmetric at the plasma membrane early during division, and
asymmetrically redistributed to the membrane of one daughter cell upon cytokinesis (Fig. 3.9 B).
As expected, expression of APT1S119A inhibited asymmetric redistribution of CDC42Palm-YFP and
retained CDC42Palm-YFP at the cytokinetic midbody (Fig. 3.9 c). I next asked whether CDC42Palm
was endogenously expressed in MDA-MB-231 cells using exon-spanning primers. I detected the
endogenous transcript for this palmitoylated CDC42 splice variant by PCR (Fig. 3.10 A, B).
Furthermore, I detected CDC42 palmitoylation in U2 OS cells by the ABE assay and
demonstrated that treatment with PalmB increased the amount of palmitoylated CDC42, whereas
treatment with the palmitoyltransferase inhibitor 2-bromopalmitate (2BP) decreased
palmitoylation (Fig. 3.10 C). These results suggest that palmitoylated CDC42 could function with
APT1 in these cells either at a basal level or in a subset of cells to promote asymmetric protein
localization.

3.7 CDC42 and APT1 interact to maintain differential activation of Notch- and Wntmediated transcription between daughter cells
In Chapter II, APT1 was determined to be required for asymmetric activity of Notch and
Wnt transcription GFP reporters (Fig. 3.11 A). I hypothesized this asymmetric reporter
expression was regulated by palmitoylation and polarity. To address this hypothesis, CDC42 and
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DHHC20 were knocked down in MDA-MB-231 cells expressing pGF1-Notch or pGF1TCF/Lef1 and asymmetric reporter signal was assessed. Knocking down CDC42 significantly
disrupted asymmetric Wnt reporter signal, whereas the Notch reporter signal was unchanged, as
compared to the pGF1-mCMV negative control (Fig. 3.11 C-F). This was consistent with
observations of asymmetric Numb localization upon CDC42 knockdown. Additionally, CDC42
and APT1 may function in the same pathway that stimulates signal-activated transcription
because double knockdown of APT1 and CDC42 did not appreciably decrease asymmetric Wnt
or Notch reporter signal over APT1 or CDC42 single knockdown (Fig. 3.11 C-F). Similar to
APT1, knocking down DHHC20 decreased asymmetric Notch and Wnt reporter expression (Fig.
3.11 C-F). Together these findings suggest palmitoylation directs the localization of a Wnt
activating factor and a Notch inhibitory factor to restrict transcription to one daughter cell.

3.8 Discussion
The data presented show an interdependence of APT1 and CDC42 activity for their own
asymmetric localization. This interdependence could occur through association of two distinct
compartments of the plasma membrane: the lipid bilayer and the membrane-associated, cortical
actin cytoskeleton. CDC42 establishes polarity in cells by spatially reorganizing the cytoskeleton
to direct vesicular traffic to and fusion with the plasma membrane (255, 257, 259). Because active
GTP-bound CDC42 is membrane-associated, APT1 could promote the recruitment of
palmitoylated proteins that also stimulate CDC42 function to the plasma membrane, e.g. the
CDC42 activator Intersectin, which is also activated by Numb (272). This is consistent with
current models of diffusible, membrane-bound molecules establishing distinct polarized domains
at the plasma membrane in a feedforward manner (8, 271). It has also been hypothesized that the
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formation of polarized domains can be inhibited if the protein association rate outpaces the
dissociation rate at the plasma membrane, or vice versa (7, 8). Constitutively GTP-bound
CDC42V12 is unable to release its substrate and has been shown to continuously accumulate at the
plasma membrane. This results in protein mislocalization at neighboring domains and eventual
loss of polarity (264, 265). This could explain why polarized membrane domains are sensitive to
changes in CDC42 protein abundance, activity, and lipid-modification, as demonstrated by the
findings presented in this chapter.
An interesting, but unanswered question, is to understand how the activity of
palmitoylated CDC42 is regulated. Palmitoylated CDC42 and prenylated CDC42 are 95% similar
in sequence, but appear to be expressed and function differently(181, 182). The palmitoylated
isoform is stably associated with membrane fractions, while the prenylated isoform is found in
both the cytosol and membrane. Additionally, palmitoylation inhibits RhoGDIα binding, another
mechanism of removing Rho GTPases at the plasma membrane in a GTP-hydrolysis independent
manner (182). Palmitoylated CDC42, but not prenylated CDC42, is required to initiate and
maintain dendrite formation and branching in neurons (183, 273). Apart from DHHC8 (85, 269),
little else is known about the DHHCs and depalmitoylating enzymes that regulate palmitoylated
CDC42 localization and function. How palmitoylation coordinates the palmitoylated CDC42
membrane localization remains to be determined. Here, I have shown that palmitoylated CDC42
is asymmetrically localized in dividing cells and this required APT1 activity, suggesting that
APT1 is one of the depalmitoylating enzymes. Additionally, palmitoylated CDC42 promotes the
asymmetric localization of β-catenin (and Numb to a lesser degree) potentially in a feedforward
manner with APT1. The data presented here also demonstrate that the palmitoylated isoform
transcript is expressed in triple receptor negative breast cancer cells, albeit at a low level.
Interestingly, expression of palmitoylated CDC42 has been detected in human breast cancer and
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prostate cancer cell lines (121, 268). Future studies may reveal whether palmitoylated CDC42 is
expressed in all cells, but at a level undetectable by conventional means, or if it is re-expressed in
disease settings which may contribute to aggressive phenotypes.
Whereas the asymmetric distributions of CDC42 and APT1 appear to be interdependent,
the depletion of either protein individually has distinct effects on the Wnt and Notch pathways.
Knocking down CDC42 significantly reduces both APT1 and β-catenin asymmetric localization,
without significantly affecting the localization of Numb. This would suggest that although
asymmetric β-catenin and Numb localization require APT1 activity, only the asymmetric
localization of β-catenin requires asymmetric localization of APT1. CDC42 is known to promote
canonical Wnt signaling activity by sequestering adenomatosis polyposis coli (APC), a
component of the β-catenin destruction complex, to the plasma membrane in an actin-dependent
manner (274, 275). Thus, maintenance of the actin cytoskeleton by CDC42 may be required for
asymmetric β-catenin localization, but not as much for Numb. As such, the requirement for
CDC42 may be necessitated by unique mechanisms of Wnt signal activation distinct from a
requirement for APT1 activity.
Little is known about the interaction between Notch signaling components and CDC42.
Notch and CDC42 have been suggested to function in parallel pathways to regulate dendrite
formation in neurons (276–278). The data presented in the chapter show Numb localization is
sensitive to CDC42 activity, consistent with a reported interaction between Numb isoforms 5 and
6 and CDC42 (279). While the results here do not show a strong requirement for CDC42 on
Notch signaling asymmetry, it is possible other polarity complexes are involved as Notch is
regulated by the Crumbs polarity complex (280, 281). How palmitoylation may regulate Notch
localization and activity at the membrane also remains to be determined.
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The connection between palmitoylation and polarity is not limited to CDC42. The
Scribble polarity complex interacts directly with CDC42 and is required for asymmetric cell
division in D. melanogaster (282, 283). Two of its members, Scribble and Discs large (also
known as SAP97 and PSD-95 in mammalian cells), are palmitoylated (53, 107, 153, 284).
Membrane palmitoylated protein 5 (MPP5), a member of the Crumbs polarity complex and
regulator of cell junction assembly, is also palmitoylated (174, 285). Future study may reveal
insights into the regulation of cell polarity by palmitoylation and potential conserved roles.
Additionally, cell polarity is thought to be a mechanism of tumor suppression (184, 286) and the
data presented here suggest modulating the palmitoylation cycle is sufficient to disrupt polarity in
cancer cell lines. It will be interesting to learn whether disrupting palmitoylation of polarity
regulators, e.g. Scribble and CDC42, is an important step in oncogenic transformation.
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MATERIALS AND METHODS

Cell Culture
MDA-MB-231 and U2OS cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No.
10566-016) and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO
(Sigma; Cat. No. D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in
DMSO, or 5 μM 2-bromopalmitate (Sigma; Cat. No. 21604-1G) prepared in DMSO for 16 hours
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for
selection.

Stable cell lines
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the
following plasmids: Scramble control, GFP-PRRL, APT1WT -CFP-Flag-PRRL, APT1 (S119)CFP-Flag-PRRL, FLAG- CDC 42 Pren -PRRL, FLAG-CDC42-V12-PRRL, FLAG-CDC42-N17PRRL, FLAG-CDC42-F28-PRRL, FLAG-CDC42 Palm-PRRL, pGF-Notch-mCMV-GFP-puro
(System Biosciences; Cat. No. TR020PA-P), pGF-TCF/Lef-mCMV-GFP-puro (System
Biosciences; Cat. No.TR013PA-P), or pGF-mCMV-GFP (System Biosciences; Cat. No.
TR011PA-1), for 24 hours with LT-1 transfection reagent (Mirus Bio. Cat. MIR2300). The
aforementioned APT1 and CDC42 plasmids were designed with short hairpin resistant sequences
for rescue studies. Virus was collected 72 hours after infection with 0.5-1mL virus used for stable
cell line generation. U2OS cells were infected with APT1WT -CFP-FLAG or APT1S119A-CFPFLAG lentivirus for 24 hours, then recovered in complete DMEM for 48 hours prior to cell
culture
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Short hairpin design
shRNA for PARD3
F: 5’CCGGGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGGCTTTTTG
-3'
R: 5'AATTCAAAAAGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGG
C-3'
F: 5'CCGGGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGGCTTTTTG
-3'
R: 5'AATTCAAAAAGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGG
C-3'
F: 5'CCGGAGTCAATTGGATTTCGTTAAACTCGAGTTTAACGAAATCCAATTGACTTTTTTG
-3'
R: 5'AATTCAAAAAAGTCAATTGGATTTCGTTAAACTCGAGTTTAACGAAATCCAATTGAC
T-3'
shRNA for CDC42
F: 5'CCGGCGGAATATGTACCGACTGTTTCTCGAGAAACAGTCGGTACATATTCCGTTTTTG
-3'
R: 5'AATTCAAAAACGGAATATGTACCGACTGTTTCTCGAGAAACAGTCGGTACATATTCC
G-3'
F: 5'CCGGTGCTTGTTGGGACTCAAATTGCTCGAGCAATTTGAGTCCCAACAAGCATTTTTG
-3'
R: 5'AATTCAAAAATGCTTGTTGGGACTCAAATTGCTCGAGCAATTTGAGTCCCAACAAGC
A-3'
F: 5'CCGGAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAATCTTTTTTG
-3'
R:
5'AATTCAAAAAAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAAT
CT-3'
shRNA for APT1
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F 5’CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’
R 5’AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘

Live-cell imaging
MDA-MB-231 cells were not conducive to studying the dynamics of asymmetric localization at
the plasma membrane by live-imaging, as these cells frequently divided out of the focal imaging
plane. Thus, U2 OS cells stably expressing mCherry-Histone H2B facilitated protein tracking
over time and allowed me to study the dynamics of asymmetric localization at the plasma
membrane over the course of cell division. U2 OS cells stably expressing APT1WT -CFP-FLAGPRRL or APT1(S119)-CFP-FLAG-PRRL were transfected with 2 μg of YFP-CDC42 PrenPCDNA3.1, YFP-CDC42 Palm-PCDNA3.1, YFP-CDC42 V12-PCDNA3.1, YFP-CDC42 N17PCDNA3.1, YFP-CDC42 F28-PCDNA3.1, for 24 hours using LT-1 (Mirus Bio; Cat. No.
MIR2300) according to manufacturer’s protocol. Cells were imaged 48 hours after transfection in
HBSS (Life Technologies; Cat. No. 14175079) containing 2% fetal bovine serum, 1 mg/mL
glutamine, and 20mM HEPES pH 7.4 at 37oC. Cells were imaged using the Leica DMI6000 B
inverted microscope.

Immunofluorescence
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in
primary antibody (β-catenin, Cell Signaling Technologies; Cat. No. 9581S; 1:500), (PARD3
(ab64646; 1:500)/ APT1 (ab91606; 1:500)/ GFP (ab290; 1:500)/ Caveolin (ab17052; 1:500),
Abcam), (DHHC20, Sigma; Cat. No. HPA014483; 1:500), (Acetylated tubulin, Santa Cruz; Cat.
No. sc23950), 1:1000), for 1-2 hours at room temperature, incubated in secondary antibody
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(Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012), Life
Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount (Southern
Biotech; Cat. No. 0100-20). Cells were imaged using the Leica DMI6000 B inverted microscope
on 40X magnification and colonies were imaged on 20X magnification.

Western Blotting
200,000 MDA-MB-231 cells were plated on 60mm tissue culture dishes and were lysed in Tris
lysis buffer (50mM Tris pH 7.4 buffer, 150mM NaCl, 2% Triton-X, 1μg/ml leupeptin, 1μg/ml
aprotinin, 2μg/ml pepstatin A). Proteins were run out on 10% acrylamide gel and probed with
PARD3 1:1000, CDC42 1:500 (Cytoskeleton; Cat. No. ACD03), Flag 1:500 (Sigma; Cat. No.
F3165), APT1 1:500, and DHHC20 1:1000, at 4ºC, overnight, then incubated in secondary antirabbit HRP (Jackson Immunoresearch; Cat. No. 211-032-171) or anti-mouse HRP (Jackson
Immunoresearch; Cat. No. 115-035-003) for 1 hour at room temperature. Blots were developed in
Piere ECL Chemilluminescence solution (Thermo Fisher; Cat. No. 32106).

Acyl-Biotin Exchange (ABE) Assay
The protocol is adapted from Wan et al., 2007 (194) : 200,000 MDA-MB-231 cells were plated
on 60mm tissue culture dishes and were harvested by scraping in ABE lysis buffer (50mM
HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 5mM EDTA, 50mM N-ethyl-maleimide
(NEM), 1μg/ml leupeptin, 1μg/ml aprotinin, 2μg/ml pepstatin A). Lysates were clarified by
centrifugation at 15,000 RPM for 10 minutes, and incubated with NEM overnight at 4ºC. The
samples were m/c precipitated twice then resuspended in 80μL 4%SDS buffer. The samples were
split in half and 160μL of hydroxylamine buffer (0.7M hydroxylamine pH 7.4, 50mM HEPES pH
7.4, 0.2% Triton X-100, 150mM NaCl, 5M EDTA) was added to one half of the sample and
control 0.2% Triton X-100 buffer (50mM HEPES pH 7.4, 0.2% Triton X-100, 150mM NaCl,
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5mM EDTA) was added to the remaining sample and incubated at room temperature for 1hour.
The samples were m/c precipitated and resuspended in 40μL4%SDS buffer containing 10μM
Biotin-HPDP (Thermo Fisher; Cat. No. 21341). 160μLof 0.2% Triton X-100 buffer +10μM
Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c precipitated and
resuspended in 20μL of 4%SDS buffer followed by addition of 800μL of 1% Triton X-100 buffer
(50μL removed for analysis as “input”). 30μL of streptavidin agarose buffer (50mM HEPES pH
7.4, 0.2% Triton X-100, 150mM NaCl, 5mM EDTA) was added to the remaining sample and
incubated at room temperature for 1hour. The samples were m/c precipitated and resuspended in
40μL4%SDS buffer containing 10μM Biotin-HPDP (Pierce). 160μLof 0.2% Triton X-100 buffer
+10μM Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c
precipitated and resuspended in 20μLof 4%SDS buffer followed by addition of 800μL of 1%
Triton X-100 buffer (50μLremoved for analysis as “input”). 30μLof streptavidin agarose beads
(Thermo Scientific; Cat. No. 20349) were added to the samples and incubated 20 overnight at 4ºC
rotating. The samples were washed in 1% Triton-X100 buffer and analyzed by SDS PAGE.

ABE Assay for Immunofluorescence
Washes were performed in 1X ABE buffer + 0.2% Triton-X + 0.1% SDS. Cells were seeded onto
coverslips. Cells were fixed in 10% formalin + 50mM NEM for 10 minutes at room temperature
and washed once before being incubated overnight in 1X ABE buffer + 0.2% Triton-X + 0.1%
SDS* + 50mM NEM at 4ºC. The following day, 3 x 15 minute washes were performed. Cells
were incubated in HA+ or HA- buffer for 2 hours at room temperature, then washed 3 x
15minutes. Cells were incubated in Biotin-HPDP buffer for 1 hour at room temperature and
washed for 3 x 20 minutes. Cells were Incubated in primary antibody (Biotin, 1:500; Abcam; Cat.
No. ab53494), at 4ºC overnight, and immunofluorescence was performed as described above.
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Quantification and linescan analysis
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in
Fig. S1A. The distribution of acquired percentage differences for each experimental condition
were plotted as dot plots. Cells with a percentage difference of 20 or greater were counted as
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ
software.

PCR
To confirm the expression of FLAG-CDC42 plasmids in shCDC42 MDA-MB-231 cells, I
isolated RNA and prepared cDNA from FLAG-prenylated CDC42, FLAG-CDC42-V12, FLAGCDC42-N17, FLAG-CDC42-F28, FLAG-palmitoylated CDC42 cell lines. PCR reaction was
performed using 2ug of cDNA, 10X PCR buffer (Sigma; Cat. No. P2192), 10mM dNTPs (Life
Technologies; Cat. no. 18252015), Taq polymerase (Sigma; Cat. No D1806) and 10μM of
hCDC42-palm and hCDC42-prenyl primers mentioned above, which are designed to span the
alternatively spliced exon. The reaction was run out on a 1.4% agarose gel.
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Figure 3.1 Schematic mechanism of establishing cell polarity. (A to C) The formation of
polarized protein domains is largely determined by a feedback of membrane association (kON) and
dissociation (kOFF) rates between the cytosolic pool and the membrane (A). If the kON outpaces
the kOFF, protein recruitment to the membrane is sustained and molecules are not removed from
the membrane quickly enough. This results in loss of distinct protein domains (B). If the kOFF
outpaces the kON, increased membrane dissociation interferes with the formation of stable
membrane domains, resulting in an expanded cytoplasmic protein pool and loss of polarized
domains at the membrane (C). Adapted from Thompson et. al. and Altschuler et. al. (8, 254)
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Figure 3.2 Asymmetric APT1 localization requires its catalytic activity in MDA-MB-231
and U2 OS cells. (A) Images of dividing MDA-MB-231 cells stained to show APT1 (red),
acetylated tubulin (green), and nuclei (blue). Arrowheads indicate asymmetric localization of
APT1. Scale bars, 15μm. (B) Distribution dot plots showing the difference in mean fluorescence
pixel intensity of APT1 across dividing MDA-MB-231 cells. The distribution of the percentage
differences of all quantified cells was plotted, and cells with a difference of >20% (dotted line)
were scored as asymmetric. (C and D) Quantifications of dividing cells showing asymmetric
APT1 when APT1WT or APT1S119A was overexpressed (C), or when DHHC20 as knocked down
with shDHHC20 (D). Cells expressing a scrambled (Scr) shRNA sequence were used as a
negative control for knockdown or overexpression. n = 302 cells scored for the experimental
group. Each dot represents a single cell. Asterisks indicate statistically significant differences
between the indicated groups. (E and F) Time-lapse images of dividing U2 OS cells
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coexpressing either APT1WT-CFP (E) or APT1S119A-CFP (F) with mCherry–Histone H2B (red).
Fluorescence pixel intensity was quantified as in (C). Scale bars, 15 µm. (G) Quantification of the
number of dividing U2 OS cells showing asymmetric APT1WT-CFP or APT1S119A-CFP
localization. Cells expressing an empty green fluorescent protein (GFP) plasmid (Vector) were
used as a negative control. n = 102 to 143 cells scored for each group from three independent
experiments. *P< 0.05 and **P < 0.01, t test and ANOVA. Error bars indicate SD.
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Figure 3.3 APT1 and DHHC20 asymmetrically partitioned with caveolin-rich membrane
domains during cell division. (A) Images of dividing MDA-MB-231 cells stained to show
endogenous APT1 (red), Numb, β-catenin, or DHHC20 (green), and nuclei (blue). (B) Images of
dividing MDA-MB-231 cells stained to show endogenous APT1 (B) or DHHC20 (C), caveolin,
and nuclei. Asymmetric localization is indicated by arrowheads (A to C). Scale bars, 15 µm.
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Figure 3.4 Asymmetric localization of bulk palmitoylated proteins in dividing cells is
inhibited with Palmostatin B. (A) Images of dividing MDA-MB-231 cells treated with PalmB
or DMSO and stained to show biotin-labeled palmitoylated proteins (red), acetylated tubulin
(green), and nuclei (blue) by ABE immunofluorescence. Samples without HAM (−HAM) were
negative controls for the ABE reaction. Scale bars, 15 µm. (B) Distribution dot plots showing the
difference in mean fluorescence pixel intensity of biotin-labeled palmitoylated proteins. The
distribution of the percentage differences of all quantified cells was plotted, and cells with a
difference of >20% (dotted line) were scored as asymmetric. n = 91 to 101 cells scored for each
experimental group. Each dot represents a single cell. Asterisks indicate statistically significant
differences between the indicated groups. (C) Quantification of the number of dividing MDAMB-231 cells showing asymmetric palmitoylated proteins after treatment with PalmB or DMSO
control. **P < 0.01 and ****P < 0.0001, t-test and ANOVA. Error bars indicate SD.
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Figure 3.5 APT1 and DHHC20 localized at the plasma membrane to domains rich in
palmitoylated proteins. Confocal images of ABE immunofluorescence in non-dividing MDAMB-231 cells showing all palmitoylated proteins (green), APT1 (A) or DHHC20 (B) (red), and
nuclei (blue) by ABE immunofluorescence. White dotted boxes indicated magnified areas shown
directly below (zoom). Samples without HAM (−HAM) were negative controls for the ABE
reaction. Scale bars (including zoom), 15 µm.
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Figure 3.6 Effect of CDC42 and PARD3 knockdown on asymmetric APT1 Numb and βcatenin localization. (A and B) Immunoblot of MDA-MB-231 cell lysates when CDC42 (A) or
PARD3 (B) was knocked down by shRNA. All subsequent experiments performed with
shCDC42 #3 or shPARD3 #3 which showed strongest knockdown efficiency compared to
GAPDH loading control. (C, E, F) Distribution dot plots showing the difference in mean
fluorescence pixel intensity of APT1 (C), Numb (E), or β-catenin (F) across dividing MDA-MB231 cells. The distribution of the percentage differences of all quantified cells was plotted, and
cells with a difference of >20% (marked by black dotted line) were scored as asymmetric. n=
160-186 cells scored for each experimental group. Each dot represents a single cell. Asterisks
indicate statistically significant differences between the indicated groups. (D, G, H)
Quantifications of dividing MDA-MB-231 cells showing asymmetric APT1 (D), Numb (G) or βcatenin (H) with shAPT1, shCDC42, double knockdown using shAPT1 and shCDC42 (DKD), or
shPARD3. Cells expressing a scrambled (Scr.) shRNA sequence were used as a negative control.
*P < 0.05; **P < 0.01, ***P < 0.001 T-test (C and D) or ANOVA (E and F- compared to Scr.).
Error bars indicate standard deviation (SD).
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Figure 3.7 CDC42 activity promotes asymmetric APT1, Numb, and β-catenin localization.
(A) PCR of FLAG-CDC42-PRRL plasmid expression of constitutively active CDC42V12 or
CDC42F28L, dominant negative CDC42N17, the prenylated CDC42 isoform (CDC42Pren), and the
CDC42 isoform that is both palmitoylated and prenylated (CDC42Palm). Cells expressing a
scrambled (Scr) shRNA sequence were used as a negative control for CDC42 knockdown, and
cells expressing the empty vector were used as the negative control for the CDC42 rescue
experiments. PRRL plasmid expression was confirmed using primers specific to the plasmid
sequence. (B) Quantification of the number of dividing U2 OS cells showing asymmetric
APT1WT-CFP or APT1S119A-CFP in cells expressing constitutively active (CDC42V12 and
CDC42F28L) or dominant-negative (CDC42N17) forms of CDC42. n = 152 to 288 cells scored for
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each group from four independent experiments. (C, E, F) Distribution dot plots showing the
mean fluorescence pixel intensity of APT1 (C), Numb (E), or β-catenin (F) across dividing cells.
The distribution of the percentage differences of all quantified cells was plotted, and cells with a
difference of >20% (dotted line) were scored as asymmetric. n= 430-465 cells scored for each
experimental group. Each dot represents a single cell. Asterisks indicate statistically significant
differences between the indicated groups. (D, G, H) Quantification of the number of dividing
cells showing asymmetric localization of APT1 (D), Numb (G), or β-catenin (H) when
constitutively active CDC42V12 or CDC42F28L, or dominant negative CDC42N17 was co-expressed
with shCDC42. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative
control for CDC42 knockdown, and cells expressing the empty vector were used as the negative
control for the CDC42 rescue experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P <
0.0001, t test (B) and ANOVA (C-H). Error bars indicate SD.
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Figure 3.8 Palmitoylated CDC42 promotes asymmetric APT1 and β-catenin localization. (A
to C) Distribution dot plots showing the mean fluorescence pixel intensity of APT1 (A), Numb
(B), or β-catenin (C) across dividing cells. The distribution of the percentage differences of all
quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored as
asymmetric. n= 241-390 cells scored for each experimental group. Each dot represents a single
cell. Asterisks indicate statistically significant differences between the indicated groups. (D to F)
Quantification of the number of dividing cells showing asymmetric localization of APT1 (D),
Numb (E), or β-catenin (F) when CDC42Pren or CDC42Palm was co-expressed with shCDC42.
Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control for CDC42
knockdown, and cells expressing the empty vector were used as the negative control for the
CDC42 rescue experiments. *P < 0.05, **P < 0.01, ***P < 0.001 ANOVA. Error bars indicate
SD.
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Figure 3.9 Spatio-temporal localization of CDC42Palm requires APT1WT activity. (A)
Quantification of the number of dividing U2 OS cells showing asymmetric APT1WT-CFP or
APT1S119A-CFP in cells expressing CDC42Pren or CDC42Palm (D). (B and C) Time-lapse images
of dividing U2 OS cells coexpressing CDC42Palm-YFP (yellow) and either APT1WT-CFP (B) or
APT1S119A-CFP (C) (blue) and mCherry–Histone H2B (red). Overlapping CFP and YFP signal in
the merge appears green. Fluorescence pixel intensity was measured along the division axis
(dashed line), and the corresponding pixel values of CDC42 (yellow line) and APT1 (blue line)
along the division axis were plotted. Red arrowheads on images and corresponding graphs mark
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the peak asymmetric CDC42 and APT1 accumulation at the membrane or cytokinetic midbody.
Time is shown in minutes (min). Scale bars, 15 µm. n = 152 to 288 cells scored for each group
from four independent experiments. ***P < 0.001 and ****P < 0.0001, t test (A to D) and
ANOVA (C and D). Error bars indicate SD.
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Figure 3.10 Expression of palmitoylated CDC42 in MDA-MB-231 and U2 OS cells. (A)
Schematic of the amino acid sequence of prenylated or palmitoylated CDC42 portraying the
alternatively spliced exon 6. Exon-spanning primers marked by arrows were designed to amplify
the alternatively spliced exon to verify expression of the isoforms in MDA-MB-231 cells. (B)
Expression of endogenous CDC42Pren or CDC42Palm in MDA-MB-231 cells by PCR using the
primers in (H). (C) Immunoblot showing biotin-labeled CDC42Palm-YFP pulled down on
streptavidin beads (PD) following ABE assay of lysates from MDA-MB-231 cell that were
treated with PalmB, 2BP, or DMSO control. Input lanes show lysate prior to pulldown. Samples
without hydroxylamine (-HAM) samples were negative controls for the ABE reactions.
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Figure 3.11 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell. (A
and B) Images of cytokinetic MDA-MB-231 cells stained to show the expression of the pGF1Notch GFP reporter (A) or pGF-1 TCF/Lef1 GFP reporter (B) (red), acetylated tubulin (green),
and nuclei (blue). Arrowheads indicate asymmetric localization. Scale bars, 15 µm. (C and D)
Distribution dot plots showing the difference in mean fluorescence pixel intensity of pGF1-Notch
reporter (C) or pGF1-TCF/Lef1 reporter (D) across dividing cells. Cells expressing an empty
pGF1-mCMV GFP reporter were used as a negative control for the reporters. The distribution of
the percentage differences of all quantified cells was plotted, and cells with a difference of >20%
(dotted line) were scored as asymmetric. n = 784 to 822 cells scored for each experimental group.
Each dot represents a single cell. Asterisks indicate statistically significant differences between
the indicated groups. (E and F) Quantification of the number of dividing MDA-MB-231 cells
showing asymmetric localization of the pGF1-Notch GFP reporter (G) or pGF1-TCF/Lef1 GFP
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reporter (H) (black bars) when coexpressed with shAPT1, shCDC42, and shAPT1 and shCDC42
(DKD). Cells expressing an empty pGF1-mCMV GFP reporter (gray bars) were used as a
negative control for reporter expression, and cells expressing a scrambled (Scr) shRNA sequence
were used as a negative control for knockdown. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P
< 0.001, t-test (between reporters and pGF1-mCMV in E, F) or ANOVA (C to F). Error bars
indicate SD.
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CHAPTER 4: ROLE FOR PALMITOYLATION ON TUMOR DEVELOPMENT

From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission
from AAAS.

4.1 Summary:
The function of asymmetric cell division, if any, on tumor development remains
contested and poorly understood. In this chapter, I present asymmetric cell division as a potential
mechanism of maintaining cellular heterogeneity in tumors, and how this heterogeneity may be
maintained by APT1 and CDC42. RNAseq analysis of MDA-MB-231 cell lines reveals APT1
expression may play a key role in regulating transcriptional programs involved in cell fate and
cancer development. I identify a role for APT1 and CDC42 on the clonogenic growth, selfrenewal potential, and population distribution of MDA-MB-231 cells. Together, these findings
suggest that palmitoylation maintains diverse cell populations, including a pool of self-renewing
tumorigenic cells, in a multi-cellular context relevant for tumor development.

4.2 Introduction
Similar to developing embryos and tissues, tumors also are comprised of phenotypically
and functionally distinct cell populations (287, 288). Within a tumor, cells can vary in the degree
of genomic instability, epigenetic modification, invasiveness, proliferative potential, and selfrenewal potential (201, 211). As the different cell populations vary greatly in therapeutic
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response, tumor heterogeneity presents a major challenge for cancer treatment and is closely
associated with aggressive disease (5, 184, 287)(Fig. 4.1 A).
The ability to form tumors is attributed to tumor-initiating cells, which exhibit properties
essential for tumor progression such as tumor formation upon single cell transplantation and
generation of diverse cell populations (227, 287, 289–291) (Fig. 4.1 B). Early studies from patient
samples revealed leukemia was predominantly comprised of post-mitotic cells, a smaller group of
highly proliferative cells, and a rare population of quiescent cells (287, 292). Subsequent studies
aimed at isolating and characterizing tumor-initiating cells from murine models and patient
derived samples by cell surface marker analysis, and report tumor-initiating cells exhibit stemcell like properties such as high proliferative potential, self-renewal, quiescence, and therapeutic
resistance in vitro and in vivo (213, 226, 227, 293–297). Importantly, cellular heterogeneity is
observed in tumors grown from a single tumor-initiating cell by surface marker and functional
analysis (226, 289, 291, 293, 298). Furthermore, tumor-initiating cells may exhibit epigenetic
alteration, genetic instability, and/or activation of metabolic pathways which promote cell
survival and heterogeneity after treatment (210, 213, 214, 288, 296). While mechanisms have
been proposed, the factors generating and maintaining tumor-initiating cells and tumor cell
heterogeneity still remain unclear and present a challenge for successful, targeted treatment
strategies.
Whether asymmetric cell division promotes tumor cell heterogeneity, as it does during
development, remains to be determined. Loss of cell polarity is a classic hallmark of oncogenic
transformation and tumor growth, and polarity regulators have been reported to function as tumor
suppressors as discussed in Chapter III (184, 251, 286). Consequently, asymmetric cell division is
also thought of as a tumor suppressor to prevent aberrant cell population expansion, which
thought to be driven by symmetric cell division within tumors (299–301). However, transformed
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cells undergo directed cell migration and directed vesicular transport, processes which required
directional protein localization, suggesting that polarity is not completely disrupted (70, 93).
Although asymmetrically dividing cells have been observed in cancer cells (218, 219, 294, 299,
302), whether these divisions contribute to tumor cell heterogeneity and disease progression is
still poorly understood.
As reviewed in chapter I, palmitoyltransferases display tumor suppressor or tumor
promoting function. In contrast, the function of depalmitoylating enzymes within tumors is
largely unknown. In this chapter, I find APT1 loss-of-function affects the transcriptional profile,
anchorage independent growth, and self-renewal potential of MDA-MB-231 cells, which are
derived from an aggressive breast cancer subtype known to exhibit a high degree of cellular
heterogeneity (298). Moreover, I observe APT1 is required for the expression of Wnt, Notch, and
Sox2 transcriptional reporters in clonogenically-derived colonies, which may correlate with
cellular heterogeneity and tumorigenicity. Furthermore, flow cytometry analysis reveals the
tumor-initiating cell population is decreased upon APT1 knockdown, implicating a function for
APT1 in the maintenance of tumorigenicity through self-renewal. With these findings, I identify
a potential role for APT1-mediated asymmetric cell division on tumor cell heterogeneity.

4.3 APT1 induces Wnt, Notch, and mammary stem cell transcriptional signatures in MDAMB-231 triple receptor–negative breast cancer cells
To date, APT1 has not been shown to drive transcriptional changes in a developmental or
disease context. To further investigate the observed influence of APT1 on asymmetric Notch and
Wnt reporter activity, I employed RNA-seq analysis of wild-type control, APT1 knockdown, or
APT1WT-expressing MDA-MB-231 cells to ask whether APT1 influences a Notch or Wnt gene
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signature (table S1). Gene set enrichment analysis (GSEA) was performed using a pre-ranked list
of differentially expressed genes and compared APT1WT-expressing cells vs. control cells, APT1
knockdown cells vs. control cells, and APT1WT-expressing cells vs. APT1 knockdown cells to
further examine whether previously defined gene signatures were altered. In APT1 knockdown
cells compared to control cells, a high scoring signature [NES (normalized enrichment score) of
1.46 and a false discovery rate (FDR) q-value of 0.073] was identified that positively correlated
with genes reported to increase with overexpression of active β-catenin (BCAT_UP.V1_UP),
suggesting APT1 is inhibitory to β-catenin signaling (Fig. 4.2 A, D). When comparing APT1WTexpressing cells to control cells, a negative correlation (NES 1.25 and FDR q-value 0.302) was
identified for a signature of genes reported to decrease upon pharmacologic inhibition of Notch
(NOTCH_DN.V1_DN). A similar pattern was observed with APT1 knockdown suggesting APT1
overexpression may function in a dominant negative manner to suppress Notch signaling (Fig. 4.2
B, D). Additionally, comparing APT1WT-expressing cells to APT1 knockdown cells revealed a
high scoring signature (NES 2.34, FDR q-value=0.0001) for genes reported to increase in
mammary stem cells (PECE_MAMMARY_STEM_CELL_UP) (Fig. 4.2 C). Visualization of the
leading-edge genes from the mammary stem cell signature also indicated a strong decrease in
expression with APT1 knockdown when normalized to control wild-type cells, (Fig. 4.2 E),
suggestive of an altered cell fate.
Two additional high scoring signatures found in APT1WT-overexpressing cells compared
to APT1 knockdown cells were signatures for Myc and Cyclin D1 overexpression, both of which
are maintained by Wnt and Notch signaling (303–305) (NES 2.08, FDR q-value 0.0001; NES
1.69, FDR q-value 0.014) (Fig. 4.2 F, G). Target genes with high log2FC (fold change) values
were validated by qRT-PCR. Notable APT1-driven genes included DKK1, BMP4, GATA6, and
KLF5 (306–308) (Fig. 4.2 H, I; table S1).
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Based on the high-scoring gene expression signature for mammary stem cells observed in
APTWT-overexpressing cells, it is possible APT1 asymmetrically restricts signaling pathways that
are activated in stem cells. The transcription factor Sox2 has been implicated in mammary stem
cell function (309), and expression of a Sox2-responsive reporter (pGF1-SRR2) revealed that its
asymmetric signal was reduced with APT1 knockdown or PalmB treatment (Fig. 4.3 AD).
DHHC20, CDC42, or APT1 and CDC42 double knockdown reduced the asymmetric SRR2
signal (Fig. 4.3 B, C, E). Asymmetric APT1 localization was also observed in dividing mouse
embryonic stem cells expressing an APT1WT plasmid (Fig. 4. 4). These results imply a role for
palmitoylation in promoting cell fate–related transcriptional signatures and maintaining
asymmetric cell division in progenitor cells.

4.4 APT1 and CDC42 maintain unique cell populations in MDA-MB-231 colonies
Triple receptor–negative breast tumors, like that from which MDA-MB-231 cells were
derived, contain subpopulations of cells that vary in proliferative, self-renewing, and tumorinitiating potential (218, 226, 228). However, whether asymmetric cell division contributes to the
generation of functionally heterogeneous cells in tumors is unclear. The colony formation assay
was utilized, which measures the growth and survival of transformed cells in anchorageindependent conditions. Because only a subset of transformed cells can form colonies, this assay
may also indicate the degree of heterogeneity within a cell population and may correlate with
tumor-initiating potential (218, 310). Knocking down APT1 reduced the colony-forming potential
of MDA-MB-231 cells by 2.3-fold (average colonies counted: shAPT1, 39 vs. Scr, 90), whereas
expressing APT1WT increased colony numbers by 1.7-fold (average colonies counted: APT1WT,
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152 vs. Scr, 90), suggesting that APT1 is required for the anchorage-independent growth and
tumorigenic potential of transformed cells (Fig. 4.5 A).
Self-renewing cells within the colony are expected to form new colonies upon serial
dissociation and replating, indefinitely. To test whether APT1-mediated asymmetry maintains a
self-renewing population within colonies, the self-renewal potential of APT1 knockdown or
CDC42 knockdown MDA-MB-231 cells in colonies was examined over 3 rounds of dissociation
and replating. APT1 knockdown significantly reduced the number of colonies on the second and
third plating, suggesting depletion of colony-initiating cells (Fig. 4.5 B). Unexpectedly, CDC42
knockdown increased the number of colonies formed with each replating compared to control
cells, suggesting an expansion of a colony-initiating cell population (Fig. 4.5 C). Colonies from
APT1 and CDC42 double knockdown cells showed reduced replating ability (Fig. 4.5 D), again
demonstrating that the expansion of this colony-forming population is dependent on APT1.
Because a significant impairment of proliferation was not observed, this result would suggest that
the reduced colony-forming potential is not due decreased proliferation under adherent growth
conditions (Fig. 4.5 E-G).
Because the increase in colony-forming potential of CDC42 knockdown cells was
unexpected, I hypothesized this could be caused by increased symmetric divisions of colonyinitiating cells. A subset of highly tumorigenic cells in basal breast cancers have been shown to
reactivate developmental signaling pathways such as those dependent on Notch, Wnt, or Sox2
(226, 298, 311, 312). Pharmacologic inhibition of Wnt (with the Porcupine inhibitor IWP2) or
Notch (with the γ-secretase inhibitor compound E) reduced the self-renewal potential of colonies
similar to APT1 knockdown or double knockdown (Fig. 4.6 A). Furthermore, APT1 knockdown
increased Wnt reporter signal and decreased Notch and Sox2 reporter signals in colonies (Fig. 4.6
B). This is consistent with GSEA analysis in Fig. 4.2 that indicated APT1 knockdown suppressed
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Notch signaling and promoted β-catenin signaling and pathways active in mammary stem cells.
Knocking down CDC42 reduced the Notch reporter signal, but increased the Sox2 reporter signal
in most of the cells within the colony (Fig. 4.6 B). The Sox2 reporter has been previously shown
to correlate with increased tumorigenicity (298); these results therefore suggest that the increase
in colony formation caused by CDC42 knockdown is due to an increase in Sox2 transcriptionallyactive cells.
To address the possibility that APT1 maintains a specific subpopulation of tumorigenic
cells, colonies were dissociated and analyzed by flow cytometry to test for the cell surface marker
profile associated with highly tumorigenic cells in breast cancers: CD44 high, CD24 low, and
Aldehyde dehydrogenase high (CD44+/ CD24lo/ ALDH+ ) (226). The size of the ALDH+
population was higher in APT1 knockdown cells (16.7%) as compared to control (7.3%) or
CDC42 knockdown (7.8%) cells on the first replating (Fig. 4.7). A difference in the cell
population distribution was observed in between colony replatings and also, cells grown in
adherent culture conditions (Fig. 4.8 A). Further gating the ALDH+ population for CD44+/CD24lo
cells revealed that knocking down APT1 reduced CD44+/CD24lo cells (2.6%), whereas knocking
down CDC42 increased this population (14.4%), as compared to control cells (5.3%) (Fig. 4.8 B).
The trend of the number of CD44+/CD24lo/ALDH+ cells being reduced in the APT1 knockdown
condition and increased in the CDC42 knockdown condition was sustained on second and third
replatings (Fig. 4.8 B). A similar pattern was observed to a lesser extent in adherent cells (Fig. 4.8
B). Consistent with the observed colony phenotypes, these results may explain why CDC42
knockdown cells form many colonies whereas APT1 knockdown cells are unable to do so. Taken
together, these findings demonstrate that in an anchorage-independent setting, an APT1-CDC42
axis maintains the expansion of a self-renewing, tumorigenic cell population and activation of
transcriptional profiles required to maintain this population.
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4.5 Discussion
By manipulating APT1 expression, I have shown that the asymmetric activation of
Notch, Wnt, and Sox2 transcriptional reporters can be altered without directly affecting the
expression of transcription factors or upstream signaling factors. The fact that β-catenin and
Notch gene signatures were not as high-scoring as compared to those of mammary stem cells,
Myc, and Cyclin D1 signatures may indicate that APT1 directs combinatorial signaling to
determine cell identity. Myc and Cyclin D1 are canonical downstream transcriptional targets of
both Wnt and Notch and are also involved in determining mammary stem cell identity (303–305).
Within the mammary stem cell signature was a notable abundance of ribosomal proteins. A
similar abundance in ribosomal proteins was also present in the Myc signature, consistent with its
role in driving ribosomal biogenesis and protein translation in the mammary gland, among other
tissues, and in cancer (313, 314). Because Myc is a critical factor for mammary stem cell identity
and function (303), these results would suggest APT1 has a role in translation in mammary stem
cells. What remains unclear is whether altering APT1 protein amounts induces the expansion of a
population of cells expressing a mammary stem cell transcriptional signature or induces a de novo
transcriptional signature in most cells. Presented here is also evidence of asymmetric APT1
localization in dividing mouse embryonic stem cells expressing APT1WT, suggesting that this
mechanism may also have a broader and conserved role in development. Future experiments
including single-cell RNAseq may address these questions.
Consistent with the concept of changing cell populations, these results suggest that APT1
is required to maintain a tumorigenic population of breast cancer cells whereas CDC42 appears to
restrict the size of this population. These findings indicate that APT1 may contribute to the
activation of transcriptional programs promoting colony-forming potential, whereas CDC42
could restrict APT1 activity to one daughter during asymmetric division. This would be
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consistent with the increase in the CD44+/ CD24lo/ALDH+ population in CDC42 knockdown
colonies. The implications of this study may be relevant to human disease because APT1 is
amplified in various cancers, and this amplification is correlated with poor patient prognosis,
suggesting APT1 could function in the development and progression of human cancers (315,
316). Although the importance of self-renewing, tumor-initiating, or stem-like cells in cancer is
still unclear, the question of how tumors maintain and generate cells with diverse properties such
as metastatic potential, dormancy, and drug resistance is still a critical one. Further exploration of
the mechanisms that establish and direct asymmetric cell division and promote cellular
heterogeneity may help us understand tumor development and progression.
Asymmetric cell division is thought to function as a tumor suppressor by restricting the
size of cell populations, e.g. stem vs. differentiated cells. Symmetric cell divisions function to
rapidly expand cell populations, allowing tissues and organisms to develop from a single cell.
Applying these principles to tumor growth suggests symmetric cell divisions are tumor promoting
(201, 299, 300). As discussed in the introduction, it is possible that asymmetric and symmetric
cell division both occur in a tumor. Asymmetric cell divisions may thus be one mechanism of
generating and maintaining diverse cell populations, while symmetric cell divisions may drive the
expansion of these various populations.
Several studies have hypothesized that asymmetric cell divisions may also function to
segregate damaged or old organelles, proteins, and damaged DNA template to prevent
propagation of damage that would result in cell cycle arrest or death (5, 31, 205, 247, 286, 317,
318). Within a tumor, this could maintain a pool of therapy-resistant cells by ensuring that cells
with sub-optimal fitness (likely to undergo treatment-induced apoptosis) are eliminated.
Currently, imaging asymmetric cell division in situ remains a major challenge, but the
development of new imaging assays and identification of asymmetric biomarkers may open up
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possibilities for imaging explanted patient samples to better understand asymmetric cell division
in disease progression (287, 294, 319, 320). Understanding all possible factors that generate
cellular heterogeneity may uncover new insights into the mechanisms of disease recurrence and
therapeutic resistance.
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MATERIALS AND METHODS

Cell Culture
MDA-MB-231 cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No. 10566-016)
and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO (Sigma; Cat. No.
D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in DMSO for 16 hours
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for
selection. E14 ESCs were cultured in DMEM Knockout (ThermoFisher. Cat. 10829-018), 15%
fetal bovine serum, 1% L-glutamine, 1% Pen Strep, 1% Non-essential amino acids, 0.1 mM 2
mercaptoethanol, 1000 units/mL Leukemia inhibitory Factor (Sigma, Cat. L5158), 1 μM MEK
I/II Inhibitor (Millipore, Cat. 444966), 3μM GSK3 Inhibitor XVI (Millipore, Cat. 361559) on
gelatin coated tissue culture plates.

Stable cell lines
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the
following plasmids: Scramble control, pGF-SRR2-mCMV-GFP-puro (System Biosciences; Cat.
No. SR20071-PA-P) or pGF-mCMV-GFP (System Biosciences; Cat. No. TR011PA-1), for 24
hours with LT-1 transfection reagent (Mirus Bio. Cat. MIR2300). Virus was collected 72 hours
after infection with 0.5-1mL virus used for stable cell line generation. E14 ESCs were infected
with APT1WT -CFP-FLAG lentivirus for 24 hours, then recovered in complete DMEM-knockout
for 48 hours prior to cell culture. MDA-MB-231 were infected with the pGF-SRR2-mCMV-GFPpuro or pGF-mCMV-GFP lentivirus for 24 hours and recovered in complete DMEM for 48 hours
prior to cell culture.

Short hairpin design
shRNA for CDC42
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F: 5'CCGGAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAATCTTTTTTG
-3'
R:
5'AATTCAAAAAAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAAT
CT-3'
shRNA for APT1
F 5’CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’
R 5’AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘

Immunofluorescence
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in
primary antibody (GFP (ab290), Abcam; 1:500) (Acetylated tubulin, Santa Cruz; Cat. No.
sc23950; 1:1000), for 1-2 hours at room temperature, then incubated in secondary antibody
(Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012), Life
Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount (Southern
Biotech; Cat. No. 0100-20). ESCs were cultured without LIF, MEK or GSK inhibitors for 24
hours before staining with 1:1000 anti-GFP (ab290) as described. Cells were imaged using the
Leica DMI6000B inverted microscope on 40X magnification and colonies were imaged on 20X
magnification.

Quantification and line scan analysis
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in
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Fig. S1A. The distribution of acquired percentage differences for each experimental condition
were plotted as dot plots. Cells with a percentage difference of 20 or greater were counted as
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ
software.

Colony Assays
MDA-MB-231 cells were plated on 6-well, low adhesion plates (Corning; Cat. No. 3471) in 2mL
of WIT-P plus serum-free supplement growth media (Cellaria; Cat. No. 00-0045-500) containing
20ng/mL FGF (Life Technologies; Cat. No. PHG0024), 20ng/mL EGF (Life Technologies; Cat.
No. PHG0311), and 10 μg /mL heparin (StemCell Technologies; Cat. No. 07980). Each well
contained 4,000 cells. Cells were treated with 1 μM GSI (Compound E; Millipore; Cat. No.
565790), 5 μM IWP2 (StemCell Technologies; Cat. No. 72124), or DMSO (Sigma; Cat. No.
D2650) and grown for 7 days before counting. For replating, cells were grown into colonies as
described. On Day 7, colonies were spun down at 1000rpm x 5min, resuspended in 0.05%
Trypsin-EDTA, reconstituted in growth media, and plated as described above. This process was
repeated for three replatings in duplicate.

Proliferation Assays
15,000 MDA-MB-231 cells were plated on a 12-well dish (ThermoFisher; Cat. No. 087723A). At
24, 48, and 72 hours, cells were washed with 1X PBS, trypsinized, and spun at 1000rpm X 5
minutes. Pellets were resuspended in DMEM and counted by a hemocytometer.

RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen; Cat. No. 74104) and cDNA
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was synthesized from 2,000ng total RNA using SuperScript III First-Strand Synthesis SuperMix
(Life Technologies; Cat. No. 18080400). qRT-PCRs were performed in triplicate using standard
SYBR green reagents and protocols on a StepOnePlus Real-Time PCR system (Applied
Biosystems). Target genes with high log2FC values were chosen for validation. The target mRNA
expression was quantified using ΔΔCt method and normalized to GAPDH expression. The
following primers were used for validation:
hDKK1
F: 5’- CAGGCGTGCAAATCTGTCT – 3’
R: 5’- AATGATTTTGATCAGAAGACACACATA – 3’
hFGF5
F: 5’- CCCAGAATCAGCCCTACAAG – 3’
R: 5’- GAGGAGGAAGGACAAGCTCA – 3’
hGATA6
F: 5’- GCAAAAATACTTCCCCCACA – 3’
R: 5’- TCTCCCGCACCAGTCATC – 3’
hKLF5
F: 5’- CTGCCTCCAGAGGACCTG – 3’
R: 5’- TCGTCTATACTTTTTATGCTCTGGAAT – 3’
hITGB4
F: 5’- TCAGCCTCTCTGGGACCTT – 3’
R: 5’- TCCTTATCCACACGGACACA – 3’
hBMP4
F: 5’- TCCACAGCACTGGTCTTGAG – 3’
R: 5’- TGGGATGTTCTCCAGATGTTCT – 3’

hPTK7
F: 5’- CAGAGGACTCACGGTTCGAG – 3’
R: 5’- TACCAGGGTCTCTGCCACTC – 3’
hGAPDH
F: 5’- ACA CCA TGG GGA AGG TGA AG-3’
R: 5’-AAG GGG TCA TTG ATG GCA AC -3’
hCDC42 palm
F: 5’-TGGAGTGTTCTGCACTTACA-3;
R: 5’-GAATATACAGCACTTCCTTTTGGG-3’
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hCDC42 prenyl
F: 5’-AGGCTGTCAAGTATGTGG-3’
R: 5’-TAGCAGCACACACCTGCG-3’

RNA Isolation and analysis for RNA-seq
Total RNA was harvested from MDA-MB-231 control, APT1WT-overexpressing or shAPT1 cells
using the RNeasy RNA isolation kit (Qiagen; Cat. No. 74104). 100ng of RNA was used to
generate cDNA libraries with the Illumina TruSeq mRNA Library Prep Kit for NeoPrep library
preparation system (Illumina; Cat. No. NP-202-1001) and reaction was performed on a
NextSeq500 sequencer. Analysis was prepared by the DNA Sequencing Facility at the Perelman
School of Medicine, University of Pennsylvania as follows: estimated transcript levels were
ranked with Salmon, TX Import was used to condense transcript levels to gene intensity, and
Deseq2 was used to calculate statistical levels for each condition. The scaled values (determined
by DeSeq2) were input to Gene Set Enrichment Analysis software (Broad Institute) and analyzed
against the C2 Chemical and Genetic perturbations, C6 Oncogenic, and Hallmark signatures gene
matrix applying classic enrichment statistic. Heat maps were generated by taking the log2 values
with an offset of 1 for all conditions and targets were chosen by taking the leading-edge targets
from GSEA BCAT, NOTCH, and mammary stem cell sets. The average of the 3 control wildtype values were subtracted from each individual value. Values were clustered for samples and
genes using Euclidean similarity measure with average linkage.

Flow cytometry
Adherent non-confluent MDA-MB-231 cells or colony-dissociated cells were treated to detect
ALDH activity using the ALDEFLUOR assay (Stem Cell Technologies; Cat. No. 01702)
according to manufacturer’s protocol. Diethylaminobenzaldehyde (DEAB) was used as a
negative control to set ALDH + gates. Cells were stained for surface markers with CD44-APC
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(BD Biosciences; Cat. No. 560890), CD24-PE (BD Biosciences; Cat. No. 560991), and
Live/Dead Violet (Thermo Fisher; Cat. No. L34963) for viability. Compensation was performed
using Ultra Comp beads (Thermo Fisher; Cat. No. 01-2222-41). Experiments were run on the
Attune NxT flow cytometer system (Life Technologies) and analyzed with FlowJo software.
ALDH+ cells (Fig. S7) were gated for CD44+/CD24lo (Fig. 7C) for comparison.
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Figure 4.1 Schematic representation of tumor cell heterogeneity on tumor development and
therapeutic resistance. (A) Increasing cellular heterogeneity is associated with aggressive, drugresistant disease. Cells may exhibit various properties such as therapeutic resistance, genomic
instability, epigenetic modification, metabolic alteration, self-renewal, and quiescence, which
promote cell survival during therapy. (B) Tumor-initiating cells are believed to exhibit stem-like
properties such as self-renewal, quiescent, and generation of diverse cell types from a single cell,
which contributes to tumor cell heterogeneity and facilitates therapeutic resistance. Tumorinitiating cells may arise stochastically from any cell within the tumor, suggesting plasticity in
cell behavior. Alternatively, tumor-initiating cells may represent a distinct population within a
cellular hierarchy. Although the mechanisms that generate and maintain tumor-initiating cells
remain unknown, this cell population represents a major challenge to overcoming drug resistance.
Adapted from Meacham et. al. and Michor et. al. (211, 287).
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Figure 4.2 Altering APT1 expression changes β-catenin and Notch gene signatures in MDAMB-231 cells. (A to C) Gene set enrichment analysis (GSEA) of a top-scoring β-catenin
overexpression transcriptional signature in MDA-MB-231 cells when APT1 was knocked down
and compared against control cells [false discovery rate (FDR) q value, 0.073] (A), a Notch
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inhibition signature when APT1WT was overexpressed and compared against control cells (FDR q
value, 0.302) (B), and a mammary stem cell signature when APT1WT was overexpressed and
compared against shAPT1 cells (FDR q value, 0.0001) (C). (D) Heat map of leading edge genes
identified in the β-catenin and Notch gene signatures shown in Fig. (A) and (B). Data are grouped
by APT1 knockdown (kd) cells, APT1WT overexpressing (oe) cells, and control (wt) cells. Genes
identified in the β-catenin signature are highlighted in green. (E) Heat map of leading-edge genes
obtained from the mammary stem cell signature shown in (C). Data are grouped by APT1
knockdown (kd) cells, APT1WT-overexpressing (oe) cells, and control (wt) cells. (F and G) Gene
set enrichment analysis (GSEA) of additional top-scoring Cyclin D1 (FDR q-value= 0.014) (B) or
Myc (FDR q-value= 0.004) (C) transcriptional signatures in MDA-MB-231 cells when APT1WT
was overexpressed and compared against shAPT1 cells. (H and I) Quantitative RT-PCR (qRTPCR) validation of target genes identified from the RNA-seq in shAPT1 (D) cells or APT1WToverexpressing (E) cells. Average fold change in expression shown by qRT-PCR (blue bars) and
RNA-seq (red bars). Graphs show average of three independent experiments.
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Figure 4.3 Asymmetric expression of a Sox2-responsive transcriptional reporter requires
palmitoylation and CDC42. (A) Images of cytokinetic MDA-MB-231 cells stained to show the
pGF1-SRR2 GFP reporter (red), acetylated tubulin (green), and nuclei (blue). Arrowheads
indicate asymmetric localization of pGF1-SRR2. Scale bar, 15 µm. (B to C) Distribution dot plots
showing the difference in mean fluorescence pixel intensity of the pGF1-SRR2 reporter (B)
across dividing MDA-MB-231 cells. Cells expressing an empty pGF1-mCMV GFP reporter (C)
were used as a negative control for the reporters. The distribution of the percentage differences of
all quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored as
asymmetric. n = 959 cells scored for the experimental group. Each dot represents a single cell.
Asterisks indicate statistically significant differences between the indicated groups. (D)
Quantification of dividing MDA-MB-231 cells showing asymmetric localization of the pGF1SRR2 GFP reporter after treatment with PalmB or DMSO control (black bars). Cells expressing
an empty pGF1-mCMV reporter (gray bars) were used as a negative control for reporter
expression. (E) Quantification of the number of dividing MDA-MB-231 cells showing
asymmetric localization of pGF1-SRR2 GFP reporter (black bars) when coexpressed with
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shAPT1, shCDC42, shAPT1 and shCDC42 [double knockdown (DKD)], or shDHHC20. Cells
expressing an empty pGF1-mCMV GFP reporter (gray bars) were used as a negative control for
reporter expression, and cells expressing a scrambled (Scr) shRNA sequence were used as a
negative control for knockdown conditions. **P < 0.01 and ****P < 0.0001, t test (between
reporters and pGF1-mCMV, D, E) or ANOVA (H). Error bars indicate SD.
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Figure 4.4 APT1WT is asymmetrically expressed of in dividing mouse embryonic stem cells.
Representative immunofluorescence of E14 mouse embryonic stem cells overexpressing
APT1WT-CFP-FLAG stained to show APT1 localization with a GFP antibody that cross-reacts
with CFP (red), acetylated tubulin (green), and nuclei (blue). Scale bars, 15 μm.
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Figure 4.5 APT1 is required for in vitro colony formation and self-renewal but is
dispensable for 2D proliferation. (A) Quantification of the average number of shAPT1-,
APT1WT- or APT1S119A-expressing colonies grown from MDA-MB-231 cells in soft agar. Cells
expressing a scrambled (Scr) shRNA sequence were used as a negative control. (B to D)
Quantification of the average number of colonies formed from MDA-MB-231 shAPT1 cells (B),
shCDC42 cells (C), both shAPT1 and shCDC42 (double knockdown, DKD) (D) over three serial
replatings. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control
for knockdown. (E to G) Proliferation curve of adherent MDA-MB-231 cells grown over 72
hours with knockdown of shAPT1 (E), shCDC42 (F), or both shAPT1 and shCDC42 (double
knockdown, DKD) (G). Cells expressing a scrambled (Scr) shRNA sequence were used as a
negative control for knockdown conditions. Each graph shows means taken from three
independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, as measured by t test. Error
bars indicate SEM.
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Figure 4.6 APT1 and CDC42 regulate the heterogeneous expression of Notch, Wnt, and
SRR2 transcriptional reporters in colonies. (A) Quantification of the average number of
colonies formed from MDA-MB-231 cells expressing shAPT1, shCDC42, both shAPT1 and
shCDC42, or control cells treated with Wnt inhibitor (IWP2), or Notch inhibitor (GSI) over 3
serial replatings. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative
control for knockdown conditions. (B) Representative fluorescence and bright field images of
colonies expressing pGF1-Notch, pGF1-TCF/LEF1, or pGF1-SRR2 GFP reporters in MDA-MB231 colonies derived from control (Scramble), shAPT1-, or shCDC42-expressing cells. Graphs
show average of three independent experiments. Scale bars, 100μm. *P < 0.05; **P < 0.01; ***P
< 0.001; ****P < 0.0001 ANOVA (A) or T-test (Scr Plating 3 vs. shAPT1 Plating 3). Error bars
indicate standard deviation SD.
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Figure 4.7 Gating scheme for ALDH+ cells on dissociated colonies or adherent cells. Gating
strategy for flow cytometry analysis to detect Aldehyde dehydrogenase expressing cells (+
ALDH) within dissociated colonies or adherent cells from Fig. 7. DEAB-treated cells served as
negative control (- ALDH) and were used to determine gating for ALDH+ cells. Size of
population denoted with percentages. Flow cytometry lots are representative of six independent
experiments.
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Figure 4.8 APT1 and CDC42 regulate the distribution of cell populations within colonies.
(A) Pie chart analysis of CD44+/CD24lo/ALDH+ , CD44+/CD24-/ALDH+ , CD44+/CD24lo/ALDH, CD44+/CD24-/ALDH- populations from cells grown in colonies or adherent. Values listed in
table as percentage. n = 8 independent experiments. Representative flow cytometry analysis
showing gating strategy of CD44+/ CD24lo cells (red box) in cells dissociated from colonies or
adherent. The population was gated off of ALDH+ cells, as shown in fig. S7. The percentages
inside the red box indicate the relative proportion of the CD44+/CD24lo cell population. Cells
were stained with phycoerythrin (PE)–conjugated anti-CD24 (CD24-PE) (x axis) and
allophycocyanin (APC)–conjugated CD44-APC (y axis). Flow cytometry plots are representative
of results from six independent experiments.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Summary
Numerous recent studies have unearthed novel roles for palmitoylation on various
cellular processes, especially during development and within tumors. However, the biological
function of the depalmitoylating enzyme APT1 still remains poorly characterized. I have
identified a mechanism for palmitoylation that regulates the asymmetric localization of the cellfate determinants in dividing cancer cells through interaction with a canonical polarity regulator
in a potential feedforward manner. In addition to protein localization, I have also demonstrated
that palmitoylation promotes the asymmetric expression Wnt, Notch, and Sox2 transcriptional
reporters between daughter cells. Suggestive of cell fate regulation, gene set enrichment analysis
(GSEA) revealed gene signatures correlating with cell identity and Wnt and Notch signaling
activity when APT1 was silenced or overexpressed. Finally, I have shown a requirement for
APT1 on the anchorage independent growth, clonal expansion, self-renewal, and cellular
heterogeneity of triple receptor negative breast cancer cells. In this dissertation, I have presented
palmitoylation as a major mechanism of asymmetric cell division that maintains Notch- and Wntassociated protein dynamics, gene expression, and cellular functions.
In Chapter 2, I utilized an RNAi approach, pharmacologic inhibition, and palmitoylationdeficient mutants to establish a requirement for palmitoylation on asymmetric Numb and βcatenin localization. For the first time, I demonstrated that human MDA-MB-231 breast cancer
cells underwent asymmetric division in vitro under normal growth conditions. By expressing Wnt
and Notch transcriptional GFP reporters, I demonstrated asymmetric reporter activity was
established by APT1 and DHHC20. These data together establish a precedent for palmitoylation
on asymmetric protein localization and downstream Notch and Wnt signaling activity.
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In Chapter 3, I employed a cell-imaging based approach to interrogate how
palmitoylation-mediated protein polarity was established. With fixed immunofluorescence, livecell imaging, and modification of the ABE assay, I observed APT1 and bulk palmitoylated
proteins were asymmetrically localized in dividing cells, and this localization required APT1
catalytic activity. Furthermore, I observed APT1 and zDHHC20 were spatially segregated to
membrane regions enriched for lipid rafts and palmitoylated proteins. Together, these data
suggest protein asymmetry may be reinforced by local palmitoylation cycles at the plasma
membrane. Utilizing point mutants of constitutively active CDC42, catalytically inactive APT1,
and CDC42 and APT1 double knockdown, I found APT1 asymmetric localization was reinforced
by CDC42 activity. Palmitoylated CDC42 was observed to also promote asymmetric APT1
localization, suggesting it is a substrate of APT1. Similar observations were found for asymmetric
β-catenin (and, to a lesser extent, Numb) localization. The data presented in Chapter 3
demonstrate an interdependence of APT1 and CDC42 activity for their own asymmetric
localization, which may regulate cell polarity in a feedforward manner
In Chapter 4, I applied GSEA on RNAseq data generated from APT1 knockdown or
expression to determine whether palmitoylation affected gene expression in MDA-MB-231 on a
global scale. I observed gene signatures associated with Wnt and Notch signaling and cell fate
determination, in addition to a requirement for palmitoylation on asymmetric Sox2 reporter
expression, a pathway implicated in stem-cell fate. Together, these results suggest a larger role
for APT1 expression on cell identity. Utilizing the colony formation and replating assays, I
discovered APT1 was required for the clonogenic growth and self-renewal of MDA-MB-231
cells. Applying flow cytometry and transcriptional reporter expression, I found the cellular
heterogeneity of colonies required APT1 (and CDC42). Together, these findings imply a role for
APT1 specifically, and palmitoylation in general, on the regulation of cell identity and function.
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This dissertation provides novel insights into the role of APT1 and palmitoylation on
cellular processes necessary for cancer and stem cell biology. In this chapter, I will outline two
key areas for further exploration to explore the role of APT1 on the cell fate determination of
progenitor cells, and during tumor development.

5.2 Understanding regulation of signaling activity by palmitoylation
Many outstanding questions remain, including the identification of palmitoylated
substrates and how the palmitoyl group affects substrate activity and localization. The
experiments proposed in this subsection seek to shed light on how palmitoylation affects cell
identity through signaling activity.
β-catenin cortical localization is mediated through association with cadherins at tight
junctions (237, 238). Having shown palmitoylation of β-catenin and enhanced downstream Wnt
activity in APT1 knockdown cells, I will examine whether β-catenin palmitoylation maintains its
stability and nuclear translocation, its cortical association, or both. A screen identified Cys466,
within armadillo repeat domains, may be palmitoylated (245). I have also identified 3 additional
cytosolic facing and potentially conserved sites (Cys429, Cys439, and Cys619) with CSS-Palm (Fig.
5.1 A). I hypothesize these four residues promote β-catenin stability to propagate downstream
Wnt, or promotes cadherin and cytoskeletal interaction. Cys429 and Cys466 are also located near a
TCF/Lef binding cleft indicating these two residues may regulate β-catenin nuclear activity (Fig.
5.1 B). Having generated single and combination point mutants of Cys429, Cys439, Cys466, and
Cys619, I will assess whether mutation of these sites affects palmitoylated β-catenin protein levels,
and if these sites sterically hinder interaction with the GSK3β-Axin2-APC destruction complex or
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cadherins. I could also test whether β-catenin palmitoylation is modulated by exogenous Wnt
stimulation to determine how palmitoylation affects downstream signaling responses.
Live-cell analysis of U2OS cells shows β-cateninWT is partitioned to the plasma
membrane of the daughter cell that emerged from the same side of the mother cell where βcateninWT was initially concentrated. APT1WT co-segregated with β-cateninWT, and was retained
in the daughter cell with high β-catenin signal as indicated by line-scan analysis of YFP and CFP
pixel intensity along the division axis (Fig. 5.1 C). Interestingly, β-cateninWT appears to be
restricted to the plasma membrane while APT1WT was predominantly cytosolic, suggesting
asymmetric β-catenin localization could be maintained in a negative feedback manner (Fig. 5.1
C). Finally, knocking down APT1 decreased the percentage of cells with asymmetric β-catenin
(Fig. 5.1 D). Using the palmitoylation-deficient mutants, I would interrogate whether these
palmitoylation deficient mutants are unable to: 1) asymmetrically localize during cell division,
and 2) localize to the plasma membrane. Further examination of GSEA signatures reveals a
negative correlation with protein-membrane trafficking in APT1 knockdown cells, supporting
conclusions that loss of protein asymmetry was due to disrupted protein transport to the plasma
membrane (Fig. 5.2 A). High resolution TIRF microscopy could also be employed to investigate
how palmitoylation affects the membrane turnover of APT1, β-catenin, and also Numb.
How palmitoylation regulates transcription is also poorly understood. To determine
whether Cys429, Cys439, Cys466, and Cys619 disrupt Wnt-induced transcriptional activity, I could
express these point mutants in pGF1-TCF/Lef1 GFP reporter cells to examine if asymmetric
reporter activity is disrupted and/or suppressed. This strategy will also be employed to examine
whether the NumbAAA palmitoylation-deficient mutant affects Notch signaling and reporter
activity.
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CDC42 did not significantly affect Numb asymmetric localization or Notch reporter
expression in daughter cells. As mentioned in Chapter 3, Numb localization may instead require
the Scribble and Crumbs polarity complexes. As components of these two complexes are known
to be palmitoylated, I could examine if Scribble and Crumbs palmitoylation-deficient mutants
disrupt Numb asymmetric localization and if Numb palmitoylation facilitates interactions with
these two complexes. This may uncover potential palmitoylation-driven crosstalk between the
CDC42, Scribble, and Crumbs complexes during the establishment of cell polarity.
A recent RNAi and misexpression screen identified wing development defects in D.
melanogaster when DHHCs were overexpressed (321), providing insights into a role for
palmitoylation on tissue morphogenesis. Positive correlations with late stem-cell differentiation in
APT1 knockdown cells and downregulation of a mammary luminal signature in APT1
overexpressing cells (Fig. 5.2 B) also support a role for APT1 on cell identity. Knocking down
APT1 was associated with suppressed 3’UTR regulation and ribosome biogenesis, while APT1WT
overexpression was correlated with chromosome segregation as compared to control cells (Fig.
5.3 A). Furthermore, APT1 overexpression or knockdown was strongly correlated with
progenitor cell identity pathways and epigenetic regulation (Fig. 5.3 B). These preliminary
findings imply APT1 may have a role on the regulation of gene expression and signaling
pathways involved in stem cell fate determination and embryonic patterning, which are also
frequently disrupted in tumors (322–326). Expression of Numb and β-catenin palmitoylationdeficient mutants in progenitor cells or in embryos would also clarify if palmitoylation is vital for
embryonic and stem cell development.
The experiments presented in this section will provide key insights into the spatiotemporal regulation of palmitoylation on protein-protein interactions and developmental
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processes. This will greatly contribute to our understanding of how developmental signaling
pathways and processes activity may be disrupted in disease progression.

5.3 Determining role of palmitoylation on drug resistance and therapeutic potential for
APT1 inhibitors
Increasing cellular heterogeneity is a key contributor to tumor recurrence, and may arise
from an accumulation of mutations as a consequence of therapeutic resistance. How distinct
tumor subpopulations inherit mutations is unclear, but may involve asymmetric cell division. In
Chapter I, various studies were described demonstrating zDHHC function on tumor progression;
in contrast, the biological function of APT1 is largely unknown. According to TCGA, APT1 is
predominantly amplified in human tumors, including invasive breast carcinomas, and may
correlate with shortened survival. Here, I will outline a strategy to examine the regulation of
survival, cellular heterogeneity, and drug resistance of tumor cells by APT1.
Cisplatin is a common first-line therapy for breast cancer, but cisplatin-resistance is
common to triple receptor negative breast cancer and contributes to poor patient prognosis (327,
328). I hypothesize loss or inhibition of APT1 may increase the sensitivity of MDA-MB-231 cells
to cisplatin. Preliminary data indicates cisplatin treatment decreases the size and number of APT1
knockdown colonies as compared to control (Fig. 5.4 A). The findings in Chapter 4 imply APT1
maintains self-renewing, tumorigenic CD44+/ CD24lo/ ALDH+ cells, which are known to be
therapy resistant and able to generate cell diversity. Further analysis of cisplatin-treated colonies
reveals an expected expansion of CD44+/ CD24lo/ ALDH+ cells, representative of drug resistant
cell, and altered population distribution. Interestingly, an approximately 1.2-fold reduction of the
CD44+/ CD24lo/ ALDH+ population was observed in treated APT1 knockdown cells as compared
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to treated control conditions (12.0% vs. 13.9%) (Fig. 5.4 B). Cell death was also increased in
APT1 knockdown cells treated with cisplatin for 72 hours as compared to control (Fig. 5.4 C).
While these observations must be validated, these preliminary findings suggest loss of APT1
increases the sensitivity of MDA-MB-231 cells to cisplatin. Importantly, repeating these
experiments in control cells treated with PalmB or ML-348 would determine if pharmacologic
APT1 inhibition: 1) phenocopies APT1 silencing, and 2) sensitizes resistant cells to cisplatin.
Sorting and replating cisplatin-treated cells would further test if the self-renewal of CD44+/
CD24lo/ ALDH+ and population distribution is exhausted by loss of APT1. I could also examine
APT1 knockdown or pharmacologic inhibition in combination with other common breast cancer
therapies (e.g. cytoskeletal disruptors, receptor tyrosine kinase inhibitors, radiotherapy, etc. (329,
330)) to assess alterations in cell survival, heterogeneity, and drug sensitivity. Repeating these
experiments with patient-derived cells in combination with organoid formation and xenograft
transplantation would give greater insights into the clinical impact of APT1 inhibition.
GSEA indicates APT1 knockdown cells are negatively correlated with DNA repair and
G2M checkpoint signatures as compared to control cells, and APT1 overexpression correlates
with chromosome segregation (Fig. 5.2 A, 5.5 A). These signatures suggest perturbations to
APT1 disrupt genome stability and cell cycle progression. Segregating DNA and damaged
organelles to one daughter cell has been proposed as a potential mechanism of ensuring stem cell
fitness and survival (205, 317, 331–333). It is entirely possible this partitioning may be employed
by tumor cells to promote the unequal inheritance of mutations, while eliminating cells fated for
apoptosis in order to promote tumor growth and metastasis. A preliminary observation of control
MDA-MB-231 cells shows asymmetric expression of the DNA repair enzymes 53BP1 and
BRCA1 in daughter nuclei (Fig. 5.5 B). This result implies that the DNA repair machinery is
recruited to the cell with greater damage, or DNA repair is suppressed in one daughter cell upon
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recruitment. I could examine the expression of 53BP1, BRCA1, Chk1, and γ-H2AX to determine
if APT1 knockdown or pharmacologic inhibition increases DNA damage. To address the
mechanism of asymmetric DNA repair, I could initiate DNA damage (drug- or radio-induced)
and examine γ-H2AX focus formation over time to: 1) ascertain unequal foci distribution
between daughter cells, 2) at what point in the DNA damage response is asymmetry first
observed, and 3) if APT1 knockdown or pharmacologic inhibition increases symmetric
accumulation of damage.
Cell death is a fate decision and may be asymmetrically induced in one daughter cell
(334). Glioma initiating cells have been reported to undergo asymmetric division and apoptosis as
well (335). I find APT1 knockdown cells positively correlate with an apoptotic execution gene
signature, which may promote the observed increase in cisplatin-induced cell death (Fig. 5.5 C).
As mentioned in Chapter I, several apoptotic regulators are palmitoylated, and thus, may be
asymmetrically partitioned or induced. Preliminary quantification of cleaved caspase-3
fluorescence intensity in non-mitotic MDA-MB-231 cells indicates increased expression in APT1
knockdown cells (Fig. 5.5 D, E). Cleaved caspase-3 is moderately increased in DHHC20
knockdown cells, implying greater specificity for apoptotic regulators not seen with APT1. I
would assess asymmetric expression of cleaved caspase-3, BAX, and Fas death receptor between
daughter cells, and determine whether cisplatin, APT1 inhibition, and combination treatment
modulates asymmetric apoptosis. Additionally, staining isolated CD44/ CD24lo/ ALDH+ would
also clarify whether APT1 knockdown or pharmacologic inhibition increases cell death, which
would contribute to a decreased tumorigenic population. These experiments would assess if
accumulating DNA damage promote cell death induced by silencing APT1.
Asymmetric organelle segregation may also be a way to induce unequal protein
translation. As shown in Fig. 5.2 A, APT1 knockdown negatively correlates with ribosome
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biogenesis and 3’UTR translational regulation. Asymmetric induction of histone modifications
have been observed in germline stem cells (336), and it is possible this process may occur in
tumor cells to differentially regulate gene expression between daughter cells. GSEA shown in
Fig. 5.2 B suggests epigenetic regulation may be altered by APT1 overexpression or knockdown.
I could assess cells for asymmetric expression of HDACs, HATs, and HMTs in control cells, and
determine if asymmetry is disrupted with APT1 inhibition. The experiments to this point would
provide insights into whether favorable mutations are unequally inherited, with implications for
the development of disease recurrence.
Ultimately, I could examine how protein palmitoylation affects signaling pathways
necessary for tumor initiation and growth. Expression of Numb and β-catenin palmitoylation
deficient mutants would determine if loss of palmitoylation inhibits or exacerbates colony
formation and self-renewal. I could also examine transcriptional Wnt and Notch reporter
expression to better understand if signaling activity is altered and if expression is symmetric
within colonies with these mutants. These experiments could be extended to other palmitoylated
substrates such as EGFR and Ras. Single RNAseq of dissociated colonies expressing Numb and
β-catenin palmitoylation deficient mutants could potentially identify novel biomarkers that could
be targeted therapeutically.
The experiment in this section can be applied to various cancer including blood, ovarian,
glioblastoma, and lung to better understand the requirement for APT1 on tumor progression.
Together, the proposed experiments would contribute to our understanding of how tumor
heterogeneity is established through asymmetric cell division, and may uncover a role for
palmitoylation inhibitors in the clinic.
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5.4 Conclusions
This work presents a conceptual framework for palmitoylation-mediated asymmetric cell
division, with implications for tumor cell heterogeneity and stem cell homeostasis. The future
experiments proposed in this chapter will build on this work to provide greater understanding into
the spatio-temporal regulation of proteins at the plasma membrane, and into the regulation of
signaling activity and gene expression during development and disease.
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Figure 5.1 Role of palmitoylation on asymmetric β-catenin localization. (A) Sequence
comparison of β-catenin armadillo repeats from fruit fly (Drosophila melanogaster), zebrafish
(Danio rerio), mouse (Mus musculus), and human (Homo sapiens). Putative palmitoylated
cysteines are highlighted in green. (B) Crystal structure of the D. melanogaster β-catenin
armadillo repeats indicating putative palmitoylated residues C429, C439, C466 and C619 in
yellow. (C) Time-lapse images of dividing U2 OS cells coexpressing β-cateninWT -YFP (yellow),
APT1WT-CFP (blue), and mCherry–Histone H2B (red). Fluorescence pixel intensity was
measured along the division axis (dashed line), and the corresponding pixel values of β-catenin
(yellow line) and APT1 (blue line) along the division axis were plotted on graphs. Red
arrowheads on images and graphs indicate the peak β-catenin and APT1 pixel intensity at the
membrane or cytokinetic midbody. Time is shown in minutes (min). a.u., arbitrary units. Scale
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bar, 15 µm. (E) Quantification of the number of dividing U2 OS cells showing asymmetric
localization of β-cateninWT-YFP in control or shAPT1 cells treated with CHAPS (black bar) or
Wnt3a (gray bar). Cells expressing a scrambled (Scr) shRNA sequence were used as a negative
control for APT1 knockdown. *P < 0.05, t test and ANOVA. Error bars indicate SD.
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Figure 5.2 GSEA signatures correlating with protein trafficking and cell identity in
APT1 knockdown or APT1WT overexpressing cells. (A and B) Gene set enrichment analysis
(GSEA) of a top-scoring protein localization to the endoplasmic reticulum, [false discovery rate
(FDR) q value, <0.0001], localization to organelles [FDR q-value= 0.03], and targeting to
membrane when APT1 was knocked down and compared against control cells [FDR q-value=
0.009] (A). Gene set enrichment analysis (GSEA) of additional top-scoring late embryonic cell
differentiation (FDR q-value <0.0001) or genes downregulated in mature mammary luminal cells
(FDR q-value= 0.007) (B).
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Figure 5.3 GSEA signatures correlating with protein translation, cell identity, and
epigenetic modification protein trafficking and cell identity in APT1 knockdown or APT1WT
overexpressing cells. (A and B) Gene set enrichment analysis (GSEA) of a top-scoring 3’UTR
mediated translation [false discovery rate (FDR) q value, <0.0001] and ribosome biogenesis
[FDR q-value= 0.0002] signatures when APT1 was knocked down and compared against control
cells. Top-scoring chromosome segregation [FDR q-value= 0.05] signature when APTWT was
overexpressed and compared against control cells (A). Gene set enrichment analysis (GSEA) of
top-scoring T lymphocyte progenitor (FDR q-value <0.0001), TGF- β signaling [FDR q-value=
0.354], and downregulation of target genes upon HDAC1 or HDAC1 pharmacologic inhibition
[FDR q-value <0.0001] when APT1 was knocked down and compared against control cells. Topscoring EZH2 target gene expression [FDR q-value= 0.007] signature when APTWT was
overexpressed and compared against control cells (B).
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Figure 5.4 APT1 knockdown may increase sensitivity of cisplatin-resistant MDA-MB-231
cells to drug treatment. A) Preliminary quantification of the average number of colonies grown
in 10m cisplatin or vehicle from MDA-MB-231 shAPT1 cells. Cells expressing a scrambled
(Scr) shRNA sequence were used as a negative control. n = 3 independent experiments. (B) Pie
chart analysis of CD44+/CD24lo/ALDH+ , CD44+/CD24-/ALDH+ , CD44+/CD24lo/ALDH- ,
CD44+/CD24-/ALDH- populations from colonies isolated in (A). Values listed in table as
percentage. n = 3 independent experiments. (C) Proliferation curve of adherent shAPT1 MDAMB-231 cells grown over 72 hours and treated with 10m cisplatin or vehicle. Cells expressing a
scrambled (Scr) shRNA sequence were used as a negative control for knockdown conditions.
Each graph shows means taken from three independent experiments. **P < 0.01, ***P < 0.001,
and ****P < 0.0001, as measured by t test (vehicle vs cisplatin) or ANOVA. Error bars indicate
SEM.
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Figure 5.5 DNA damage repair and apoptosis may be dependent on APT1. (A) Gene set
enrichment analysis (GSEA) of a top-scoring DNA repair [false discovery rate (FDR) q value,
0.094] and G2M checkpoint [FDR q-value= 0.147] signatures when APT1 was knocked down
and compared against control cells. (B) Representative immunofluorescence of cytokinetic MDAMB-231 control cells stained to show asymmetric or symmetric 53BP1 or BRCA1 (red),
acetylated tubulin (green), and nuclei (blue). Scale bars, 15 μm. (C) Gene set enrichment analysis
(GSEA) of a top-scoring apoptotic [FDR q-value= 0.398] signature when APT1 was knocked
down and compared against control cells. (D) Representative immunofluorescence of nondividing MDA-MB-231 shAPT1 or scrambled (Scr) control cells stained for cleaved caspase 3
(red), acetylated tubulin (green), and nuclei (blue). Scale bars, 30 μm. (E) Distribution dot plots
showing mean fluorescence pixel intensity of cleaved caspase 3 signal of MDA-MB-231 shAPT1
(D) and shDHHC20 cells. Cells expressing a scrambled (Scr) shRNA sequence were used as a
negative control for knockdown conditions. n = 127 cells scored for the experimental group from
1 experiment. Each dot represents a single cell
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